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Portfolio Thesis Abstract 
 
Purpose  
Chapter one used the Self-Regulation Model (SRM) of health beliefs as a framework to 
review results from psychological interventions that utilised health belief outcomes based on 
the SRM  for people with Functional Neurological Disorder.  The empirical chapter used 
demographic, psychological and healthcare utilisation outcomes to explore the efficacy, 
feasibility and acceptability of a brief intervention for routine care for people with FND 
designed to address a gap in current service provision within NHS Grampian.  
Method  
A systematic search strategy identified seven studies for inclusion in the review chapter.   
Chapter two compared the data of attenders (n=16) and non-attenders (n=13) on 
demographic, psychological and healthcare utilisation variables.   Data from group 
completers was collected at four timepoints and included cognitive function, mood, quality of 
life, health beliefs, healthcare utilisation and costs; Participant knowledge and experiential 
data was also collected.   
Results 
Chapter one showed studies were of mixed quality with studies being rated as satisfactory 
(n=4) unsatisfactory quality (n=3).  Higher quality studies had more comprehensive selection 
and data management processes than lower quality studies.   In chapter 2 non-attenders rated 
their physical health limitations as significantly more and perceived less personal control than 
attenders. Completers showed significant improvements in understanding of FND and in 
levels of fatigue were reported as significantly less at follow up. No differences between 
attenders and non-attenders for healthcare utilisation or costs.  63% of completers showed 
improved health status at follow up, participant expectations were met. knowledge of FND 
significantly improved. The content and format of the intervention were acceptable to 
participants 
Conclusions 
Taken together both chapters highlighted the role of health beliefs in FND but also  the 
importance of providing access to appropriate information and peer support for those 
receiving a diagnosis.   The brief intervention showed promising results in terms of efficacy, 
feasibility and acceptability.  Although further research will be required to ascertain if these 
findings are sustainable in a larger sample long term.    
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Systematic Review Abstract 
Introduction    
This systematic review aimed to explore the pattern of health beliefs of people with 
Functional Neurological Disorder (FND) after taking part in psychological interventions as 
indexed by measures based on the self-regulation model of health beliefs.  
Methods   
A systematic review using a pre-determined search strategy was undertaken. Searches 
of electronic databases and sources of grey literature were searched from January 1995 to 
January 2020. In addition, references of included studies as well as studies citing the included 
studies were manually searched.   
Results  
Seven studies were included in the review,  studies were evaluated against quality 
criteria based on the Newcastle Ottawa Scale.  Results showed four studies met criteria for 
rating as satisfactory and three studies were found be of unsatisfactory quality.  Overall 
studies rated as higher quality were found to be most robust in their selection processes, 
utilising relevant statistical analysis and made efforts to identify and control for confounding 
variables.   Studies rated as poorer quality tended to detail in justifying their methodology 
and lack specificity when reporting and analysing outcome data.  
Conclusion   
There was provisional evidence to suggest psychological interventions have potential 
to change the maladaptive beliefs those with FND may have about their symptoms.  
However, the methods around analysis and reporting of health belief outcomes in non-
randomised research lacked consistency.     
Keywords 
Health beliefs; Illness perception; Functional Neurological Disorder; Psychological 




Functional Neurological Disorder (FND) refers to the physical manifestation of 
neurological symptoms that have no organic basis as there is no detectable damage to the 
nervous system.  Symptoms are real, not imagined and can be as debilitating both physically 
and psychologically as organic disease (Stone, Carson and Sharpe, 2005). The terminology 
used to describe FND has been a source of debate in the past with the condition being 
referred to as hysteria, dissociative, psychogenic, psychosomatic, somatoform, conversion 
and medically unexplained (Edwards, Stone & Lang, 2014). More recently there  has been a 
shift in labelling these neurological symptoms as functional which is thought to remove 
speculation around the aetiology of presenting symptoms (Edwards et al.,  2014).  The use of 
the label ‘functional’ appears not only to be perceived as less offensive to those receiving a 
diagnosis but is also being adopted as the term of preference for clinicians treating those 
living with symptoms (Rommelfanger, Factor, LaRoche, Rosen, Young & Rapaport, 2017; 
Stone, Wojcik, Durrance, Carson, Lewis, et al., 2002).  
There is a lack of epidemiological research around FND which may be due, to the 
complexity of categorising symptoms clinically and the diagnosis process (Carson & Lehn, 
2016).  As symptoms can be varied there has been debate historically regarding how to 
conceptualise and categorise the symptoms (Carson & Lehn, 2016).  Although this appears to 
be improving with a focus, in the DSM V, on patterns of symptoms that cannot be attributed 
to organic neurological conditions (Carson & Lehn, 2016).  As a result of this complexity, 
FND can be difficult to diagnose without extensive experience of neurological conditions  
(Carson & Lehn, 2016).  For example a study investigating  a diagnosis of FND made by 
General Practitioners (GP) found that the accuracy of diagnosis was at chance level (Carson, 
Ringbauer, Stone, McKenzie, Warlow & Sharpe, 2000) where as those diagnosed by 
Neurologists were more robust over time (Stone, Carson, Duncan et al., 2010).  This 
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discrepancy raises the importance of the level of clinician training and knowledge levels 
when accurately diagnosing FND (Carson & Lehn, 2016).  As a result the most valid figures 
for prevalence of FND should be taken from settings where neurologists are undertaking the 
diagnosis which may make the cost of multi-centred, worldwide epidemiological studies 
prohibitive (Carson & Lehn, 2016).   
There is a limited range of research available exploring the prevalence of FND within 
a Neurology clinic setting with the majority of research being based in the UK finding 
prevalence rates of FND between 26% and 45% (Bateman & Harrison, 2000; Carson et al., 
2000; Stone et al., 2010; Stone & Sharpe, 2002; Stone, Sharpe, Deary, I., & Warlow., 2004).  
There is also some variability within international research studies.  For example a study in 
the Netherlands found 35% of patients presented with medically unexplained symptoms 
where as an Australian study showed 15% of outpatients presented with FND (Ahmad & 
Ahmad, 2016).     
In Scotland around one third of patients presenting to neurology clinics based have 
FND related symptoms (Carson et al., 2000; Stone, Carson, Duncan, Roberts, Coleman et al.,  
2012; Stone & Sharpe, 2002; Stone et al., 2005). FND can present in many forms including 
non-epileptic attack disorders, tension headache, limb weakness, abnormal movement, 
cognitive and sensory problems.  It is common for patients with FND to have comorbid 
physical and mental health conditions and/or a functional overlay to symptoms of 
neurological conditions such as epilepsy (Stone et al., 2012).   
Patients with FND are the largest clinical group accessing neurology clinics. In 
Scotland, 5,000 people per year receive a diagnosis of FND, this is important for healthcare 
services as the healthcare utilisation of patients with FND is estimated at double that for those 
without (Healthcare Improvement Scotland, 2012).  Estimated costs for healthcare service 
providers within  Scotland are £1.3 million for outpatient services, £6.01 million for 
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inpatients and £4.01 million for primary care services (Healthcare Improvement Scotland, 
2012).        
In addition to scheduled care, there is evidence people with FND present regularly for 
unscheduled care such as the emergency room (Cock & Edwards, 2018).  Guidelines for 
treating and managing symptoms of FND have recently begun to emerge.  Healthcare 
Improvement Scotland (2012) recommend a 4-level stepped care model starting with a robust 
explanation and validation of the FND diagnosis through to step 4 with patient pathways and 
clinician training.  This report also highlighted a lack of consistency relating to evidence 
based therapeutic interventions in FND.  The inconsistency came from the heterogeneity of 
delivery methods and patient outcome measures which made it difficult to generalise findings 
across studies (Division of Neuropsychology, 2013). 
There is tentative evidence that health beliefs are an important predictor of progress 
12 months later for those with FND (Sharpe, Stone, Hibberd, Warlow, Duncan et al., 2010). 
A potential mechanism for the development of beliefs around our subjective health comes 
from both personal experience and external information from the environment  (Hotopfet, 
Mayou, Wadsworth, & Wessely, 1999).  In childhood the misinterpretation of symptoms 
which is  reinforced by parents can lead an individual to believe that their perceived health is 
poorer than their actual health (Benjamin & Emminson, 1992).  This pattern of thinking can 
continue into adulthood resulting in an inaccurate concept of current health state (Benjamin 
& Emminson, 1992).  Environmental information can also be acquired in a secondary 
manner, for example those with FND often have experienced family health problems 
(Hotopfet al.,1999).  Information from the media about symptoms relating to illness can also 
be internalised and result in higher numbers of people presenting with concerns they have the 
condition in question (Stewart, 1990).  A potential mechanism for maladaptive beliefs may 
result from both personal experience and secondary sources of information contributing to 
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the beliefs an individual accesses when making sense of the symptoms they are experiencing 
(Hotopfet al.,1999).   
There is also evidence that patients with FND hold a significantly stronger belief that 
psychological factors do not contribute to their symptoms when compared to  patients with 
organic neurological conditions  (Stone, Binzer & Sharpe, 2004). This belief that symptoms 
originate from an organic source has been identified as a potential defining feature of FND 
previously, however the dismissing of psychological factors may also be an artefact of the 
diagnostic process where a medical explanation for their symptoms that the patient finds 
credible has not been achieved (Stone et al., 2004). This is important as there is also evidence 
to suggest those with negative health beliefs are less likely to be reassured when results of 
medical tests come back normal (Donkin, Ellis, Powell, Broadbent, Gamble & Petrie, 2005) 
which may lead to increased healthcare utilisation searching for the ‘right’ diagnosis. 
Psychologically based treatment programmes have been identified as being a potential 
mechanism in helping patients reframe their beliefs previously (Stone et al., 2004).  However, 
there appears to be a disparity in the literature with emerging evidence from related clinical 
guidelines that psychological interventions are an appropriate treatment but people with FND 
have difficulty engaging in mental health related services (Monzoni,  Duncan, Grunewald &  
Reuber, 2011).  The language used in the explanation given as to why there is a lack of 
physical source for the symptoms has perceived by those receiving the diagnosis as their 
symptoms being dismissed as imaginary or fictious (Stone et al., 2002).  This interpretation 
can mean patients resist acceptance of an FND diagnosis covertly by not engaging with 
services or more overtly, by disputing the diagnosis (Monzoni et al., 2011). This behaviour 
could  potentially be understood in terms of the Self-Regulation Model (SRM) with the 
refusal to attend mental health services due to the beliefs a person with FND has constructed 
about their illness.  Sharpe et al. (2010) utilised items from the Illness Perception 
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Questionnaire in their study (Weinman, Petrie, Moss-Morris, & Horne., 1996). This is an 
outcome measure derived from the SRM (Leventhal, Meyer & Nerenz., 1980; Leventhal, 
Nerenz, & Steele.,1984) that theorises that health beliefs are important factors contributing to 
the level of symptoms being experienced as part of an in illness.   
The Self-Regulation Model (SRM) 
  In the SRM the person experiencing the symptoms operates as an active agent.  The 
processes within the SRM occur simultaneously rather than in stages (Leventhal et al., 1980; 
1984).  For example, when a person responds to a perceived threat to their health, a response 
to assist an understanding of the symptom becomes activate which allows meaning of the 
symptoms to be constructed.   There are several factors thought to contribute to the patterns 
of meaning people perceive when facing a health threat according to the SRM (Leventhal et 
al., 1980; 1984).   
The first component in the SRM is the cognitive representation that is developed by 
the individual. In the SRM, this cognitive representation underpins several other factors 
related to the illness experienced.  Illnesses and disorders have a diagnostic label attached, 
some illnesses are culturally accepted and have no positive or negative connation’s for most 
people e.g. the common cold or influenza.  However, sometimes labels are stigmatised in 
society and if a label from an illness with negative connotations is attributed to a person, they 
may internalise these.  This process of responding to the diagnostic label and the attached 
societal meaning given to a health condition is called illness identity in the SRM model (see 
Figure 1).   According to the SRM, any response to the label assigned will be based on the 















Figure 1 Schematic representation of a health threat in The Self-Regulation Model in FND.   
Included and adapted for FND with kind permission from Parfeni, Nistor and Covic, 2013). 
 
The SRM theorises that the perception of how long the illness will last is based on 
how the illness is represented cognitively.  For example, depending on what is understood by 
the type of illness, there will be expectations from the person experiencing symptoms 
whether these will occur as a one-off experience, if they will last for a period of time or come 
and go at intervals.  Responses to the cognitions around expected duration of symptoms are 






According to the SRM, potential causes in terms of whether internal or external 
factors are responsible for the illness developing will also be held in the cognitive 
representation, this is referred to as the causal attribute.   Other factors contributing here 
include, the age of the individual, their prior experience of symptoms and the degree of 
success they have achieved trying to manage these.  Experience from these factors also feed 
into the casual attribute in the model providing feedback as to whether anything can be done 
to control the symptoms (Leventhal, Halm, Horowitz, Leventhal, Ozakinci et al.,  2004).  
Beliefs held around management and recovery from illness are called the control/cure 
attribution in the SRM.  These cognitions centre around expectations about the extent to 
which the illness can be managed or cured either by the body itself or with medication and/or 
other methods of intervention (Leventhal, Forster, Leventhal, Aldwin, Park, & Spiro, 2007).  
Expectations around what will happen as a result of having the illness is the consequence 
attribute within the SRM.  Consequences of illness in the SRM can be categorised into four 
factors; physical function, personal, social and economic factors (Leventhal et al., 2007).   
In addition to the cognitive representation of the perceived health threat held in the SRM, 
there is a representation relating to how emotional responses to the illness are represented 
within the individual experiencing symptoms.  Emotional reactions occur in parallel and link 
to how the threat is positioned cognitively (Leventhal et al., 2007).  For example, symptoms 
persist despite efforts to control these and an emotional reaction of anxiety and low mood 
may occur as a result (Leventhal et al., 2007).  The cognitive and emotional representations 
of illness in the SRM feed in to coping strategies which informs how the illness is viewed.   
This cycle of symptom appraisal in the SRM is a dynamic process with symptoms being re-
evaluated when new information or changes are perceived. This can lead to changes in both 
how the illness is experienced physically and coped with emotionally (Horne & Weinman, 
1998).   
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Previous research has identified that negative health beliefs can be detrimental to 
speed of recovery from illness  (Donkin et al, 2005; Frostholm, Fink, Christensen, Toft, 
Oernboel, et al., 2005; Petrie & Weinman, 2006) and link to higher levels of healthcare 
utilisation (Frostholm et al., 2005).  Negative health beliefs are common in those 
experiencing illnesses with a functional basis, such as chronic fatigue (Knoop, Prins, Moss-
Morris & Bleeijenberg, 2010), fibromyalgia (Glattacker, Opiz & Jackel, 2010) and irritable 
bowel syndrome (Rutter & Rutter, 2002).    Taken together these studies indicate the utility of 
the SRM in providing a framework by which to consider the role of health beliefs in FND, 
however there are also limitations of the model to consider. 
An obvious limitation of the SRM is it considers beliefs about the illness in isolation 
from other beliefs that an individual may hold about factors that may also influence recovery 
(Horne, 1997). For example beliefs about the appropriateness of the treatment  on offer and 
the subsequent impact this has on patient engagement with the treatment process.  This may 
be especially relevant for people with FND result in rejection of psychologically based 
treatment as they do not believe this is an appropriate treatment for their personal symptom 
profile (see Stone, Carson & Hallett, 2016).  The attrition rates of people with FND from 
therapeutic interventions may be a demonstration of this.  The SRM does not consider level 
of knowledge or the accuracy of pre-existing knowledge a patient holds about their condition.  
Often patients are not aware of what FND is and may have already established views that 
they have another diagnosis which can interfere with acceptance of an FND diagnosis (Stone 
et al., 2016).    This review aims to establish if there are common themes of change within 
health beliefs after therapeutic intervention for those with FND using outcome measures 
based on the SRM.  
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Outcome Measures Based on the SRM 
In order to evaluate health beliefs in illness using the framework of the SRM, three 
quantitative outcome measures have been developed the Illness Perceptions Questionnaire 
[IPQ (Weinman et al., 1996)]; the IPQ-Revised [IPQ-R; (Moss-Morris, Weinman, Petrie et 
al., 2002)] and  the Brief Illness Perception Questionnaire [IPQ-B; (Broadbent, Petrie, Main 
& Weinman, 2006)].  Responses on the IPQ measure (Weinman et al., 1996) were initially 
divided into five scales assessing the components of cognitive representation of the illness: 
identity; timeline; control/cure; causal and consequences.   A disadvantage of the original 
IPQ was the emotional representations of the illness were not considered in the instrument.   
The omission of the emotional representation was corrected when the IPQ was revised to 
include an item to represent this factor (the IPQ-Revised or IPQ-R)  (Moss-Morris et al., 
2002).   Although this measure saw the inclusion of emotional representations held by the 
patient, the length of the questionnaire meant it took participants a significant amount of time 
to complete.   
The third outcome measure based on the SRM was a briefer version of the  
IPQ-R, called IPQ-B (Broadbent et al., 2006).  The IPQ-B consists of nine items rated on a 
scale from zero (minimum) to ten (maximum). Cognitive representations are measured by 
items one to five;  perceptions such as effect on life (item one); length of time illness will last 
(item two); level of perceived control over illness (item three); beliefs around the 
effectiveness of treatment (item four); and beliefs about symptoms (item five). Emotional 
representations are explored by beliefs concern about illness (item six) and mood (item 
eight).  The item on coherence measures how well the illness is understood (Item seven).  
Item nine is free text and offers space for the patient to rank what three things have caused 
their symptoms.  A total score can be obtained which represents the level of threat perceived 
from the illness.  To calculate the total score items three, four and seven are reverse coded 
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and added to the other items, a higher score is indicative the illness is perceived as more 
threatening (Broadbent et al., 2006).  This measure is quick to complete and straight forward 
to interpret making it useful when working with people experiencing problems with their 
health.   
Health Beliefs in FND 
Negative health beliefs using the IPQ outcome measure have been found previously 
to be predictive of poorer health outcomes in FND (Sharpe et al., 2010).  The research by 
Sharpe et al., (2010) used a prospective cohort design to collect data from Scottish Neurology 
clinics.  Beliefs surrounding the permeance of symptoms and the magnitude of belief that 
psychological factors contributed to symptoms were measured using items from the IPQ 
(Weinman et al. 1996).  
An additional factor predictive of outcome was receipt of health-related state payment 
benefits. It was suggested that receiving benefits may provide further validation to the 
symptoms and related levels of disability thereby contributing to the ongoing presence of 
FND (Sharpe et al., 2010).  These findings contradicted the initial hypothesised outcomes 
would be dependent on the number of physical symptoms, the perceived level of disability 
and the severity of symptoms from anxiety/depression participants experienced (Sharpe et al., 
2010).  
This research utilised a design reflective of methods in clinical practice  to explore 
health beliefs in an FND population, within the Scottish healthcare system.  This result fits 
with evidence from other functional disorders where health beliefs negative in valence also 
resulted in poorer health outcomes (Glattacker et al, 2010; Knoop et al., 2010, Rutter & 
Rutter, 2002).  There is a lack of treatment options available for those living with the 
condition to access (Division of Neuropsychology, 2013).   Evidence to date has made it 
difficult to make a judgement regarding the clinical utility of introducing a therapeutic 
 18 
intervention. For example, a study may measure changes perceived in physical symptoms 
(Mayor, Brown, Cock, House, Howlett et al., 2013); whereas others may explore changes in 
psychological experience (Conwill, Oakley, Evans & Cavanna, 2014) meaning it is difficult 
to capture overall benefits to patients taking part in therapeutic interventions.  
 Review Aims and Objective 
In line with Sharpe et al., (2010), this review will focus on studies that mirror clinical 
practice and exclude research designs which do not e.g. Randomised Control Trial (RCT) 
designs.  The decision to exclude RCT designs is bipartite.  Firstly, the heterogeneous nature 
of the population with FND means that the controls may not reflect the same pattern of 
difficulties as the experimental group.   Secondly, designs using outcome measures 
administered pre and post intervention are more reflective of outcomes collected in clinical 
practice. Exploring studies closer to clinical practice may be helpful in identifying potential 
patterns of change in the health beliefs of people with FND that take part in psychological 
interventions within clinical rather than research settings.  
An additional facet of the study by Sharpe et al., (2010) is that health beliefs were 
quantified using measures based on the SRM.  A limitation highlighted previously with 
developing an evidence base for effective treatment of FND was the heterogeneity of delivery 
methods and patient outcome measures in the research to date (Division of Neuropsychology, 
2013).  As a result, this review will also focus on studies utilising outcome measures based 
on the SRM namely the IPQ, IPQ-R and IPQ-B to consolidate evidence on one measure.  As 
these measures are quantitative in nature no qualitative studies will be included in the review.  
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The overall objective of this review is to address a key gap in the current literature by 
exploring what elements of health beliefs as indexed by the SRM change for people 
diagnosed with FND after taking part in psychological interventions.  Studies reporting 
outcomes based on the SRM for patients both pre and post engagement in a psychological 
intervention with and without a follow up will be included.   
Method 
  
 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines on how to undertake systematic reviews (Moher, Shamseer, Clarke, Ghersi, 
Liberatiet al., 2015) alongside guidance from the Centre for Reviews and Dissemination 
(CRD, 2009) informed the process of the current review (see Figure 2).  Prior to conducting 
the full systematic review, preliminary literature searches were undertaken of the 
International Prospective Register of Systematic Reviews (PROSPERO) and the CRD to 
ensure that a review in this area had not been published previously or was currently registered 
as an active project.  Scoping searches for potential review topics related to brief 
interventions for FND conducted prior to the current review included the efficacy of 
psychological interventions for FND and psychoeducation for FND.  However, these topics 
had already been registered on the PROSPERO website resulting in a change of focus for the 
current systematic review topic.   
Inclusion and Exclusion Criteria 
Criteria for study inclusion and exclusion were developed using the ‘PICOS’ 
(Population, Intervention, Comparison, Outcome, Study design) model. (CRD, 2009). 
Population 
Adult patients (aged 16+) with a diagnosis of FND or a historical or alternative 
diagnostic equivalent were included e.g. conversion disorder; dissociative disorder; 
functional neurological symptom disorder; functional neurological symptom; functional 
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movement disorder; nonepileptic attacks; psychogenic symptoms; psychogenic non epileptic 
seizures (PNES); somatoform symptoms. 
Intervention  
Psychological interventions delivered either individually or in a group which included 
patient health beliefs as part of the outcomes for people with FND were included. 
Interventions had to be based on well-established psychological principles such as cognitive 
behavioural therapy (CBT), acceptance and commitment therapy (ACT), psychoeducation, 
mindfulness etc.    
Comparison  
No control group was required for inclusion.  Pre and post treatment measures where 
participants acted as own control.  
Outcome  
Studies that reported measures of health beliefs/illness perceptions based on the self-
regulation model IPQ; IPQ-R; Brief-IPQ.  Studies were excluded if qualitative or mixed 
methods analysis were used.   
Study Design 
Observational studies with quantitative methodology were included. Studies were 
excluded if they were published in non-peer reviewed media (e.g. conference abstracts) or 
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Literature Search Strategy 
A systematic search was undertaken between January 1995 to January 2020: Ovid 
MEDLINE, PsycINFO, The Cochrane Register, EMBASE and Web of Science. The British 
Library Electronic Theses Online System (EThOS), and Google Scholar search engines were 
used to explore grey literature.   
Search terms were based on previous research and current clinical documents were 
developed for capturing terms used for FND, health beliefs and psychological therapy in 
previous literature (see Table 1). 
Table 1 Search strategy used in the systematic review 
 
The search strategy identified 233 studies.  PICOS criteria were used to screen the 
titles and abstracts of studies to determine their suitability for inclusion.    After screening, 
seven studies were identified as suitable for inclusion in the systematic review.  All reference 
lists of the articles included in the review and articles citing the included papers were also 
searched to identify further papers.  The protocol for this review was published by 
PROSPERO  (see 
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019158075h )   
Area Search Terms Used 
FND 
("conversion disorder*" or "dissociative disorder*" or "functional 
neurological disorder*" or "movement disorder*" or "Functional 
neurological symptom*" or "FND" or "PNES" or "nonepileptic" or 
"non epileptic" or "NEAD" or "somatoform" or "psychogenic 
symptom*"). 
Health Beliefs 
("self-regulation" or "self-regulation" or "health belief*" or "illness 
perception*" or "health perception*" or "IPQ" or "common sense" or 
"patient attitude" or "illness cognition*" or "illness representation"). 
Psychological 
Intervention 
(((Cognitive behav* or CBT or psychological intervention* or 
psychological therap* or psychoeducation* or ACT or Acceptance) 
and Commitment*) or Psychother* or Brief Intervention* or 
Mindful* or Group Therapy* or Guided self* or Psychodynamic*). 
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Data Extraction  
PI (reviewer one) screened the title and abstract of studies using the review search 
strategy and compared against the inclusion/exclusion criteria. LM, a third-year trainee 
clinical psychologist (reviewer two) checked the data extracted for 4 papers randomly 
selected.    Extracted data will be managed in a Microsoft Excel database prior to transferring 
to tables in the review document.   References were managed by RefWorks to identify and 
remove duplicate articles.  
Quality Assessment 
The Newcastle Ottawa Scale assesses study quality using a star system over three 
categories: Selection (5-star maximum score), Comparability (maximum 2 stars) and 
Outcome (maximum 4 stars).  The Newcastle Ottawa Scale is the recommended instrument 
for assessing non-randomised research (Julian, Higgins & Green, 2011) and has previously 
been used with outcome measures based on the SRM in systematic reviews in both physical 
health (Parfeni, Nistor & Covic, 2013) and a population with sudden onset neurological 
conditions (McAleese & Guzman, 2017).  
For the purposes of this review the Newcastle Ottawa Scale was applied in the following 
way:  
Selection / Representativeness (* per item) 
1. Did the participants in the study represent people with FND in the community?  
2. Were the number of participants justified, was the study sufficiently powered? 
3. Were the differences between those taking part and not taking part explored and 
was the rate of recruitment satisfactory? (e.g. attrition rate between 5% and 20%) 
4. Were the variables of interest in the study captured with validated outcome 
measures? 
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5. Was the version of the IPQ outcome measure used in line with the developers’ 
recommendations?  
 Comparability (* per item) 
6. Was there evidence that the study controlled for relevant predictors/risk 
factors/confounding variables (e.g. duration of symptoms?)  
Outcome (* per item) 
7. Was the assessment of outcome completed by independent blind assessment or 
unblinded assessment using objective validated laboratory methods * 
OR Used non-standard or non-validated laboratory methods (e.g. double assessment of 
scored items * 
8. Was follow up long enough for outcomes to occur with a clearly described and 
reported relevant statistical test? * 
9. Were all subscales of the IPQ version used reported? * 
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In line with recommendation from the Centre for Reviews and Dissemination that 
quality assessment tools are adapted to reflect the aim of review.  The Newcastle Ottawa 
Scale was amended with the inclusion of 2 items.  The first item was added to the selection 
category to ascertain if the outcome measures based on the SRM are utilised in the study in 
line with the recommendations of the questionnaire developers.  The second question was 
added to the outcome section to ensure the subscales of the IPQ were reported accurately and 
as recommended by the questionnaire developers (see Appendix 2). 
High quality studies will be awarded   9-11 stars, Good Studies: 7-8 stars, Satisfactory 
Studies: 5-6 stars and Unsatisfactory Studies: 0 to 4 studies.  PI (reviewer one) screened the 
title and abstract of studies using the review search strategy and compared against the 
inclusion/exclusion criteria. LM, a third-year trainee clinical psychologist (reviewer two) 
checked the data extracted from a subset of papers.  It is recommended to minimise bias a 
minimum of two reviewers assessed the quality of the studies selected for inclusion (SIGN, 
2015).  Four of the included papers (57%) were selected at random and rated by LM 
(reviewer two), interrater reliability was found to be 80%.  Discrepancies were discussed and 
resolved.  The supervisory team were available to review independently if there were 




Study Characteristics  
 
In line with the inclusion criteria of this review, all studies were prospective pre-post 
design, except for one which adopted a retrospective design (Saifee, Kassavetis, Pareés, 
Kojovic, Fisher, et al., 2012).  There were 3 studies that included a follow up period between 
6 months (Goldstein, Deale, O’Malley, Toone & Mellers, 2004), 1 year (Demartini, Batla, 
Petrochilos, Fisher, Edwards, et al., 2014) and a median of 7 years (Saifee et al., 2012).      
The number of participants ranged from 9 – 66, with participants being predominantly 
female, the percentage of males participating ranged from 11% - 48%.   Most studies (n=4) 
had participants only with non-epileptic attacks (Cope, Smith, King, & Agrawal, 2017; 
Goldstein et al., 2004; Williams, Howlett, Levita, & Reuber, 2018; Wiseman, Mousa, 
Howlett, & Reuber, 2016). The remaining 3 studies included people with other types of FND.  
All studies reported the duration participants had experienced symptoms which ranged from 
3.6 years (Blake, Abilitt, Ruffmann, Morley, Williams et al., 2019) to 7.1 years (Cope et al., 
2017). Employment rates were reported by all studies apart from one (Blake et al., 2019).  
The percentage of participants economically inactive ranged from 48% (Cope et al., 2017; 
Wiseman et al., 2016) to 87.5% (Goldstein et al., 2004).   
Two studies delivered interventions within an inpatient rehabilitation setting 
(Demartini et al., 2014; Saifee et al., 2012), the remaining five studies were outpatient based.   
Outpatient sessions ranged from three sessions lasting 90 minutes (Cope et al., 2017) to 20 
sessions lasting 50 minutes (Williams et al., 2018).  CBT was the most frequent modality 
used in the interventions with all studies drawing on this model except for Williams et al., 
(2018) who adopted brief augmented psychodynamic interpersonal therapy (BAPIT).  Most 
of the therapy was delivered on an individual basis except for two studies which adopted a 
group format (Blake et al., 2019; Cope et al., 2017).   
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Illness perceptions were measured most frequently using the IPQ-B in three studies 
(Cope et al., 2017; Williams et al., 2018; Wiseman et al., 2016), two studies utilised the IPQ 
(Goldstein et al., 2004; Saifee et al., 2012) and two used the IPQ-R (Blake et al., 2019; 
Demartini et al., 2014).  
Four out of seven studies used changes in symptoms as an outcome with all of these 
finding that participants symptoms improved post intervention (Cope et al., 2017; Goldstein 
et al., 2004; Saifee et al., 2012; Wiseman et al., 2016).  Most studies (n=4) included measures 
evaluating the participants’ experience of the intervention (Blake et al., 2019; Cope et al., 
2017; Saifee et al., 2012; Wiseman et al., 2016).  The characteristics of the included studies 









Table 2 Characteristics of Included Studies 


















No of participants 
 n = 9 
Age 




Type of FND 
3xPNES; 1 x Sensory; 
6xFunctional Motor symptoms 
Duration of Symptoms 
M=3.6 years (SD = 3.6) 
Recruitment 
10/16responded 




2-hour sessions  
Number of sessions 
6 Sessions  
Group frequency not reported 
Modality: CBT based on 
existing manual 
Delivered By 
MDT Approach 1x Neurology;  
1x Neuropsychology;  
1 x physiotherapy;  
2 x psychology; 1 x nurse 









Not all subscales 









Patient Experience  
55% found helpful 
Reduced feelings of isolation 
More time for discussion 
Some felt no relevance to their 
symptoms and content too 
generic  
Outcomes  
Decrease in HADS score 
Increase in SF36 Phys and 
psych role limitations; social 
function; health change 
Decrease of 1.56 points on 
















No of participants 
 n = 16 
Age 








Type of FND 
PNES 
Duration of Symptoms 
M=7.1 years (SD = 6.6) 
Recruitment 
Number invited not reported 






Number of sessions 
3 Sessions  
Modality: CBT  
Group Therapy  
Delivered By 
Clinical Psychologist 
Staff experience: Formal 
Clinical Psychology training 
Data Timepoints 
Pre-therapy; Post-therapy; 







Not all subscales 
















40% (7/18) Attack Free post 
intervention 
Patient Experience  
Felt less alone, reduced feelings 
of isolation.  Valued space to 
share coping mechanisms.  
Prefer longer sessions and a 
follow up group. 
Outcomes  
Statistically significant 
improvements in ET7 and 
IPQB subscales relating to how 
long illness will continue 
Levels of concern and 
understanding of illness. 






























































et al., 2014 
Design: 
Prospective Longitudinal  
Follow Up 12 months 




No of participants 
 n = 16 
Age 




Type of FND 
PNES 
18.75% (n=3) psychiatric 
comorbidities  
Duration of Symptoms 
M=3.6 years (SD = 3.6) 
Recruitment 
20/20 responded 
16/20 took part pre-post 
Employment 
Pre: 87.5% not employed (n=11 
Unemployed; n=3 students) 
Pre: 95% health related benefits 
Duration:  
Initial session 2 hours  
Additional sessions: 60 minutes 
Weekly or Fortnightly 
Number of sessions 
12 Sessions  
Modality: CBT  
Individual Therapy  
Delivered By 
CBT Therapist (Nurse) 
Staff experience: Formal CBT 
training & supervision 
Data Timepoints 
Pre-therapy; Post-therapy; 










Causes Physical (Pre 
m=1.91 SD =0.58; 
Post 1.56 SD = 
0.49); Consequences 
(Pre m=3.71 SD 
=0.59; Post 3.32 SD 
=0.59) Control/Cure 
(Pre m=3.19; SD 
=0.52; Post 3.86 SD 
= 0.74) 
Self-Report 







81.25% either seizure free or 
50% less seizure activity 
Patient Experience  
Not reported 
Outcomes  
Significant improvement from 
Pre – Post maintained at F-Up 
WSAS  
Avoidance decreased Fear 
Q’aire 
HADS Anxiety and depression 
IPQ (see previous column)  
Employment 
31.25% (n=5; 4 previously 
unemployed; 1 student) moved 











Follow Up 12 months 




No of participants 
 n = 66 
Age 




Type of FND 





Duration of Symptoms 
M=4.8 years (SD= 3.2) 
Recruitment 
Consecutive patients admitted 
between 2006-2008 
26/32 responded 
19/26 took part pre-post 
Employment 
Pre: 71% not employed  
Pre: 95% health related benefits 
Duration:  
4-week inpatient  
Number of sessions:  
Max of 20 (5 x Therapy over 4 
weeks).   
Modality: CBT  








Neurology assessment and 
input 
1 x nurse 
Staff experience: Not reported 
Data Timepoints 





























Not reported  
Patient Experience  
Not measured 
Outcomes  
Significant increase Subscale: 
Illness coherence Significant 
increase pre-post & F-Up 
Subscale: Illness coherence  
Significant Reduction pre-
post & F-Up Subscale: 
Emotional representation 
timeline (acute/chronic) 
illness coherence  
emotional representation 
between pre and post changes  
12 month Follow up group 





Table 2 Continued 













Pre-Post (time between 
measures M=11.0 months; 
SD = 7.1) 





No of participants 
 n = 44  
Age 
M=41.5 (SD = 13.5) 
Gender 
77.3% (n=34) Female 
22.7%  (n=10) Male 
Type of FND 
PNES 
Other – No information 
Duration of Symptoms 
5.4 years (SD=10.8) 
Recruitment 
Consecutive patients  
118/127 consented 
72/118 completed Pre 
44/72 completed Post 
Employment 
Pre: 63% economically inactive 
(Unemployed, on benefit, retired 
ill health or old age) 
Duration:  
Initial session 2 hours  
Additional sessions: 50 minutes 
Number of sessions:  
Maximum = 20 





1 x psychotherapist 
 









Only overall illness 
threat score reported 
Mean reduction in 
IPQ-B reached 
significance at post 
(m=48.83; SD = 
15.79) compared to 
Pre (M=55.51; SD = 












Patient Experience  
Not reported 
Outcomes 
Emotion processing improved 
post treatment. 
Health related QoL improved  

















4 x centre multisite 
 
 
No of participants 
 n = 25 
Age 




Type of FND 
PNES 
Duration of Symptoms 
5.3 years (SD=9.1) 
Recruitment 
Consecutive patients  
36/40 responded 
29/36 attended  
25/29 Completed 
19/25 gave post-feedback 
Employment 
Pre: 13/25 52% in work  
Duration:  
1hour Psychoeducation 
Number of sessions:  
4 x 1 hour 
Modality: CBT  
Individual Psychoeducation 
Delivered By 
3 x Assistant Psychologists 
1 x Occupational Therapist 
6 x Specialist Epilepsy Nurses 
 












Only overall illness 
threat score reported 
Mean reduction in 
IPQ-B reached 
significance at post 
(m=42; SD=21.3) 
compared to Pre (M 























6/25 seizure free for 1 month 
6/25 reduced seizure activity 
Patient Experience 
86% completed 96% reported 
found helpful 92% felt helped 
to control seizures 
100% of these recommend  
42% (8/19) agreeing to 
psychological constructs being 
causative post compared to 
22% Pre (5/23) no stats for this 
Outcomes  
No significant relationship 
between duration of illness and 
outcomes  
CORE-10 significant decrease 
in psychological distress  
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No of participants 
 n = 19 
Age 




Type of FND 
68% Functional Motor symptoms 
16% Weakness 
16% Fatigue 
Duration of Symptoms 
>3years 
Recruitment 
Consecutive patients admitted 
between 2006-2008 
26/32 responded 
19/26 took part pre-post-
Employment 
Pre: 16% in work  
Pre: 91% health related benefits 
Duration:  
4-week inpatient  
Number of sessions: 5 x 
Therapy Weekly.   
Modality: CBT  








Neurology assessment and 
input 
1 x nurse 
 
Staff experience: Not reported 
Data Timepoints 
Admission; Discharge; Follow 
Up  
 
Based on Self-help book 























58% improved  




65% found CBT helpful 
58% reported found helpful 
74%  of these recommend  
26% would not 
 
Outcomes  
No difference in which member 
of MDT most useful 
Correlation between 
participants reporting benefit 
and agreeing to psychological 
constructs being causative  
  
Employment 
19% of patients in work at 
follow up (non-significant) 
 
1 CNSQ = Common Neurological Symptom Questionnaire; CORE-10 = Clinical Outcomes in Routine Evaluation 10; CORE-OM = Clinical Outcomes in Routine Evaluation Outcome Measure; 
COPM= Canadian Occupational Performance Measure; DES-II = Dissociative Experiences Scale II; EPS-25 =Emotional Processing Scale 25; EQ-5D = EuroQoL 5 dimensions;  
ET7 = Revised Emotional Thermometer Scale; GAD-7 = Generalised Anxiety Disorder Scale; HADS = Hospital Anxiety & Depression Scale; HoNOS = Health of the Nation Outcome Scale;  
IPQ-B = Illness Perception Questionnaire Brief; IPQ = Illness Perception Questionnaire; IPQ-R = Illness Perception Questionnaire Revised; MHLC = Multidimensional Health Locus of Control; 
MHS = Mental Health Summary; NewQOL-6D = QALY measure for Epilepsy; PHQ-9 = Patient Health Questionnaire 9; PHQ-15 = Patient Health Questionnaire 15;  
PHS = Physical Health Summary; SF-36 = The Short Form 36; WSAS = Work and Social Adjustment Scale 
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Applying the Newcastle Ottawa Scale Quality Criteria  
 
The quality assessment using the Newcastle Ottawa Scale suggested that four studies 
were categorised as satisfactory scoring between five and six stars on the quality rating (Cope 
et al., 2017; Demartini et al., 2014; Williams et al., 2018; Wiseman et al., 2016).  Three 
studies were categorised as unsatisfactory (Blake et al., 2019 ; Goldstein 2014; Saifee et al., 
2012) scoring between two and four stars (See Table 3).   
Selection 
All studies scored between two and four stars in this section.  Three studies met 
criteria for the representativeness of those with FND included in the studies and how it 
compared to people with FND in the community (Demartini et al., 2014; Saifee et al., 2012; 
Williams et al., 2018;.    One study recruited using multiple sources of referral, including 
neurology, psychiatry and GP’s (Goldstein et al., 2004) however, this study and two others 
also used exclusion criteria which has implications for generalising the findings to the FND 
population.   For example, two studies excluded participants with active psychiatric 
conditions (Blake et al., 2019; Cope et al., 2017), with two studies excluding patients with 
comorbid organic neurological conditions (Blake et al., 2019; Goldstein, 2014). 
No formal power calculations were provided by any of the included studies. There 
were also no justifications regarding the number of participants that were recruited, resulting 
in no stars being awarded for any of the studies in this area  (Blake et al., 2019; Cope et al., 
2014; Demartini et al., 2014; Goldstein et al., 2004; Saifee et al., 2012; Williams et al., 2018; 







Table 3 Quality Rating for Studies Included in the Review 




















et al.,  
(2012) 
Selection 
Representativeness of FND 
Truly represents average person with FND in the community  
OR 
Somewhat represents people with FND in the community 
 
- - - * * - * 
Sample size Justified and satisfactory (including sample size calculation)  - - - - - - - 
Non-respondents Proportion of target sample recruited  - - * * * * * 
Ascertainment of the exposure Validated Outcome measures * * * * * * * 
IPQ/IPQ-R/IPQ-Brief administration Consistent with developers’ recommendations * * * * * * - 
Comparability 
Confounding variables controlled for. 
Data/Results controlled for relevant predictors/ 
risk factors/confounders (**) 
OR 
Used non-standard/validated methods (*) 
- ** - - - ** - 
Outcome 
Assessment of outcome 
Independent blind assessment/record linkage (**) 
OR 
Unblinded assessment using objective validated lab methods (**) 
- - - - - - - 
Follow Up 
Was follow up long enough for outcomes to occur with a clearly 
described and reported relevant statistical test? * 
- * * * * * * 
IPQ/IPQ-R/IPQ-Brief reporting Subscales reported in full - - - - - - - 
Overall Quality Rating1 (Minimum = 0 Maximum =11)   2 5 4 5 5 6 4 
1Very good: 9-11 stars; Good 7-8 stars; Satisfactory 5-6 stars; Unsatisfactory 0 to 4 stars 
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The number of non-respondents in the reviewed studies was generally low, with two 
studies recruiting all the participants they invited (Demartini et al., 2014; Goldstein et al., 
2004).  Most of the others had between 7% - 18.75% not responding to the invitation to 
participate (Williams et al., 2018; Saifee et al., 2012; Wiseman et al., 2016).  Out of the 
remaining studies, 37.5% of those invited did not respond (Blair et al., 2019) and one study 
did not report recruitment figures (Cope et al., 2017).   
All studies utilised standardised outcome measures to collect data on the variables of 
interest (Blake et al., 2019; Cope et al., 2017; Demartini et al., 2014; Goldstein et al., 2004; 
Saifee et al., 2012; Wiseman et al., 2016; Williams et al., 2018).    
Six studies appeared to administer their version of the IPQ in line with the developers’ 
recommendations (Blake et al., 2019; Cope et al., 2014; Demartini et al., 2014; Goldstein et 
al., 2004; Wiseman et al., 2016; Williams et al., 2018).   The remaining study administered 
only part of the IPQ (Saifee et al., 2012)  
Comparability 
All studies had predominantly female participants.  This fits with the clinical profile 
of FND which is thought to be more common in females with prevalence ranging between 
60-75% for those diagnosed (see Carson & Lehn, 2016). The mean age of participants in the 
included studies fitted in general with the age of average onset of FND reported to occur 
most often between the ages of 35–50 years old (see Carson & Lehn, 2016).  However, FND 
is also common in men and can occur at any point over the lifespan (see Carson & Lehn, 
2016).   Only one study did not report a mean or median age, choosing instead to report 
frequency of age categories (Cope et al., 2017).  
Diagnosis of FND in the participants was completed by neurologists in five studies 
(Blake et al., 2019; Cope et al., 2014; Demartini et al., 2014; Wiseman et al., 2016; Williams 
et al., 2018).   One study (Goldstein et al., 2004) reported diagnosis was made by a 
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neuropsychiatrist, who utilised video-telemetry, thought to be the gold standard for diagnosis 
of non-epileptic seizures (Gedzelman & LaRoche, 2014). The final study had diagnosis 
confirmed by a multi-disciplinary team, which included neurologists (Saifee et al., 2012).  It 
is considered unusual for FND to be present as a stand-alone set of symptoms.  Common 
comorbidities often found in FND include pain, fatigue, weakness and sensory disturbances 
(Carson et al., 2000; Kim, Pakiam, & Lang, 1999; Koller, Lang, Vetere-Overfield, Findley, 
Cleeves et al., 1989).  
Participants with active psychiatric conditions were excluded from three studies 
(Blake et al., 2019; Goldstein et al., 2004; Wiseman et al., 2016) however dissociation in 
non-seizures may be trauma related (Holmes, Brown, Mansell, Fearon, Hunter et al., 2005), 
therefore excluding on this criterion may be potentially omitting participants with 
predisposing factors to FND.  
The presence of comorbid organic neurological conditions resulted in participants 
being excluded in two studies (Blake et al., 2019; Cope et al., 2017). Organic neurological 
conditions are also found more frequently in people with FND, occurring in approximately 
one in ten cases, which is higher probability than chance (Stone, et al., 2012).  The exclusion 
of participants may risk selection bias in the sample.  However, there also needs to be 
consideration regarding the safety of the participant and the ethical dilemma of including the 
patient in a research project whilst managing risks associated with poor mental health (e.g. 
risk of suicide and/or self-harm).   
Outcome 
All the included studies received no stars for outcome assessment.  The studies did 
not include a control or comparison group therefore assessing the outcome by independent 
blind assessment was not possible in the delivery of the included intervention.   The use of 
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other methods to minimise bias in the scoring of outcome assessments, such as double 
scoring of assessments, was not reported by any of the included studies, resulting in no stars  
on this category of the Newcastle Ottawa Scale.  Finally, all the studies used outcomes 
potentially subject to bias as the measures were self-report.   
Follow up periods varied between six months (Goldstein et al., 2004); one year 
(Demartini et al., 2014; Williams et al, 2018) and two years (Saifee et al., 2012).  The sample 
sizes in one study led to it being so underpowered an analysis using inferential statistics was 
not possible (Blake et al., 2019).  However, the remaining studies used appropriate statistical 
analysis and were all awarded a star on the Newcastle Ottawa Scale.   
Assessment of the scoring and subsequent reporting of the included versions of the 
IPQ resulted in no studies reporting the subscales of their chosen measure in full.  In addition, 
no study reported if Cronbach’s alpha coefficients, in line with developer recommendations, 
were reported.  There was no justification provided to support the omission of the reliability 
calculation or the omission of the items subscales in any of the included studies (Blake et al., 
2019; Cope et al., 2017; Demartini et al., 2014; Goldstein et al., 2004; Saifee et al., 2012; 




A meta-analysis was not considered for the current review due to the lack of 
homogeneity in the included study’s methodology for variables such as the duration of 
sessions, the number of sessions and the variety of outcome measures used.  
Two studies utilised a group format (Blake et al., 2019; Cope et al., 2017).  However, the lack 
of inferential analysis of data in the second group study (Blake et al., 2019) does not allow 
these interventions to be compared.   
Three of the included studies consisted of interventions only for participants with 
non-epileptic attacks.  These were delivered in a group (Cope et al., 2017) and one to one 
format (Goldstein et al., 2004; Wiseman et al., 2016). Two of these studies utilised a 
cognitive behavioural model of treatment, using the IPQ-B as their index of health beliefs 
(Cope et al., 2017; Wiseman et al., 2016). The studies were similar in number and duration of 
sessions (3 x group sessions of 90 minutes; Cope et al., 2017; 4 x individual sessions of 1 
hour); There were also differences in the level of experience of the facilitators with the 
individual session having less experienced staff compared to the group.  Improvements were 
found in both studies post intervention for IPQ-B. Unfortunately, both studies reported their 
findings differently making comparison difficult.   The group study reported individual 
subscales; three subscales measuring perception of how long the illness will continue, levels 
of concern and how well FND was understood showed significant improvement post 
intervention. However, the composite score representing level of threat perceived by the 
participant was not reported (Cope et al., 2017).  In the one to one intervention, the level of 
threat perceived significantly reduced post intervention. However, individual subscales were 
not reported (Wiseman et al., 2016).  Neither study reported significant changes in another 
shared outcome, the Work and Social Adjustment Scale (Mundt, Marks, Shear & Greist, 
2002).  Similar reductions in levels of participants’ reporting being symptom free at the end 
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of the intervention were found in both studies (40%, Cope et al., 2017; 48%, Wiseman et al., 
2016).  Duration of symptoms was also unrelated to study outcomes in both interventions 
(Cope et al., 2017; Wiseman et al., 2016), however gender differences were not explored. 
Both studies incorporated participant feedback. This showed comparable levels of 
acceptability, indicating that the interventions were found to be helpful to those participating.  
An additional benefit of the group programme, highlighted in the feedback, was the potential 
that meeting others with the same diagnosis helped participants feel less isolated (Cope et al., 
2017).  This theme of feeling less isolated as a result of a group intervention was also 
reported in participant feedback for another study (Blake et al., 2019).     
Individual therapy for Psychogenic Non-Epileptic Seizures using an alternative 
psychological model of brief augmented psychodynamic interpersonal therapy (BAPIT) also 
chose the IPQ-B in their outcomes (Williams et al., 2018).  This sample was mixed FND, 
however initially data were originally analysed as two participant groups; those with PNES 
and those with other types of FND symptoms.  As no significant differences were found 
between the subsets of participants, data were collapsed by the authors across the different 
types of FND, creating a sample of mixed FND pathology.  Participants in the BAPIT 
intervention reported a similar level of perceived threat from their FND to the intervention 
that also utilised a cognitive behavioural approach on a one to one basis (Wiseman et al., 
2016). Both studies reported significant reduction in the level of threat perceived from FND 
using the composite score from the IPQ-B and interpreted this effect as evidence of 
improvement in how the participants understood their FND (Williams et al., 2018; Wiseman 
et al., 2016).  In contrast to the Wiseman et al (2016) study, Williams et al., (2018) did not 
include a measure of participant experience, therefore this cannot be compared across the 
studies.   Furthermore, neither study included a follow up component to their research so the 
robustness of this effect cannot be determined.   
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Other studies using one to one with a mixed population were both undertaken by a 
multi-disciplinary team, within an inpatient rehabilitation setting (Demartini et al., 2014; 
Saifee et al., 2012).  Both studies had a sample of participants with mixed FND pathology 
that took part in a 4-week inpatient intervention.   One study found a statistically significant 
improvement at the end of treatment on the subscales of the IPQ-R.  These were indexing of 
understanding of FND (illness coherence) level of distress experienced as a result of symptoms 
(emotional representation); symptoms as being less likely to be permanent (timeline 
acute/chronic) and felt to have less impact on their life (consequences) (Demartini et al., 2014).  
Attrition was high with 45% of those participating lost to follow up.  However, for those who 
completed 12-month follow up differences were found post treatment and sustained for 
improvement in illness coherence and emotional representation (Demartini et al., 2014).    In 
addition to health beliefs, 64% rated their FND symptoms as improved and 67% reported their 
general health was better or much better.  
An earlier study with a different cohort of patients from the same inpatient programme 
conducted a retrospective follow up with a median of seven years (Saifee et al., 2012). Fifty eight 
percent of those who had participated in the intervention previously reported a sustained level of 
improvement compared to the symptoms they recalled when they took part (Saifee et al., 2012).    
The index of health beliefs was the IPQ in this study which revealed that at follow up participants 
believed that emotional state (27%) and ‘stress’ (50%) was causative.  A correlational analysis 
found that those reporting psychological factors as potential causes appeared to benefit 
significantly more from the intervention (Saifee et al., 2012). 
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An additional study (Goldstein et al., 2004), also conducted a follow up analysis also 
using the IPQ but in an outpatient setting in a participant population with PNES.   A significant 
difference was also found in this sample of participants for the belief that emotional factors had 
contributed more to their FND than physical factors, this difference remained significant at 6 
months follow up (Goldstein et al., 2004).    Other subscales of the IPQ reported in this study 
revealed that there was no significant change with regards the expected timeline of experiencing 
FND.   However, there were significant improvements around the perceived impact FND would 
have on their life (consequences) and an increase in the amount of control perceived over 
symptoms (control/cure).   All significant difference found post-treatment remained at the six 




   Treatment options for FND are in their infancy, with preliminary guidelines lacking 
clear direction for clinical services in how to operationalise the recommendations.  There is a 
lack of consistent evidence for the best approach to treating FND with emerging guidelines 
lacking clarity on how to put their recommendations into practice.  As a result, this review 
opted to focus on health beliefs which have been shown to be a valid predictor for recovery in 
FND previously (Sharpe et al., 2010).  The beliefs identified were related to the permeance of 
symptoms and the magnitude to which psychological factors contributed to the symptoms 
being experienced.  As Sharpe et al., (2010) utilised items from the IPQ (Weinman et al. 
1996) which is based on the SRM, this review included treatment options utilising 
psychological therapy and including outcome measures based on the SRM.   
As the guidelines for FND are to help embed treatment options in routine clinical 
practice, the results of the review are based on non-randomised studies that incorporated a 
health belief outcome measure based on the SRM as part of evaluating a psychological 
intervention for people with FND.  The overall aim of this systematic review was to 
investigate if health beliefs for people diagnosed with FND change after taking part in 
psychological interventions. 
All studies, that used inferential statistics, reported improvements in the health belief 
measures for participants taking part in psychological interventions.  In terms of successful 
outcome, there appeared to be no added benefit to having one to one in contrast to group 
therapy.  Indeed, group interventions may have added benefits in being more cost effective in 
terms of resources but also may indirectly address feelings of isolation in those with FND 
(Blake et al., 2019; Cope et al., 2017).   
 
 42 
There appeared to be commonalities across subtypes of FND within the included 
study with regards health beliefs with no condition specific patterns being reported.  Most 
included studies utilised a cognitive behavioural therapeutic approach, however, participants 
taking part in a BAPIT intervention showed similar reductions in the level of threat they 
perceived when compared to individuals taking part in a CBT based therapy (Williams et al., 
2018; Wiseman et al., 2016).  
The findings of the included research showed participants had more acceptance for 
psychological factors contributing to their FND symptoms post-intervention and at follow up 
(Demartini et al., 2014; Goldstein et al., 2004; Saifee et al., 2012).  Participants also reported 
a greater understanding of FND across studies (Cope et al., 2017; Demartini et al., 2014; 
Saifee et al., 2017; Williams et al., 2018; Wiseman et al., 2016).  Saifee et al., (2012) found 
that participants made better progress over time if they reported more acceptance of 
psychological factors contributing to symptoms, which fits with the findings from previous 
research (Sharpe et al., 2010).   
Four out of seven studies were rated satisfactory in quality (Cope et al., 2017; 
Demartini et al., 2014; Williams et al., 2018; Wiseman et al., 2016).  These studies tended to 
be robust in terms of recruitment ensuring a sample representative of those with FND in the 
community and showed smaller rates of attrition (Demartini et al., 2014; Williams et al., 
2018).  All studies utilised validated measures for their outcomes and the majority used their 
version of the IPQ in line with the developer’s recommendations.     
Areas of poorer quality related to controlling for potentially confounding variables, 
the use of self-report outcomes and the use of (or lack of reporting of) methods to minimise 
bias (e.g. having two people score outcome measures) were not used in the study method.  
Although all the IPQ health belief measures appeared to be administered correctly, there 
appeared to be a lack of consistency with the developer’s recommendations of stating all 
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subscales on an individual basis and reporting the internal reliability within the sample, 
resulting in no studies earning stars in this area.   
The area of research targeted by this review is novel and has evidence to suggest the 
area of health beliefs has predictive validity with patient outcome (Sharpe et al., 2010).  In 
addition to a systematic search strategy, citation records were also consulted both for papers 
cited within the reference list of included papers and for papers citing the papers included.  
To address selection bias, a second reviewer (LM) also compared the selected studies against 
the review inclusion/exclusion criteria in addition to applying the quality criteria.   
This review was limited as it contained only non-randomised studies.  A further 
limitation was the authors of the included papers were not contacted to ascertain if the 
information regarding the non-reported subscales or scoring methods were available.  In 
addition, only papers written in the English language were included potentially leading to a 
language bias within the review.  How generalisable the results for this review are is difficult 
to decide based on these results alone.  There were limited number of papers including health 
beliefs in their outcomes of therapy and those with small sample sizes may result in studies 
that were underpowered to detect effects on all measures (Blake et al., 2019; Cope et al., 
2017; Goldstein et al., 2004; Saifee et al., 2012; Wiseman et al., 2016).    Many studies were 
also cross-sectional with health beliefs as a secondary outcome rather than a main variable of 
interest (Blake et al., 2019; Cope et al., 2017; Wiseman et al., 2016) 
Future research should consider the potential benefits of including an objective 
measure of health beliefs when conducting research in the efficacy of interventions for people 
with FND.  Incorporating a follow up period where possible to explore the temporal aspect of 
these changes and determining if changes translate to meaningful improvements in function 
for participants would hold clinical utility. Although duration of symptoms was considered in 
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some analyses (Cope et al., 2017; Wiseman et al., 2016) these relationships were 
correlational within small samples.   
It would be interesting to look at health beliefs and resulting outcomes for newly 
diagnosed participants taking part in psychological therapy to see if the timing of therapy has 
an impact on health beliefs.  Exploring the impact of the experience level of the intervention 
facilitators on group outcomes could also be a useful study.   The conclusion of this review is 
that there is tentative evidence to suggest psychological interventions have potential to 
change the maladaptive beliefs people hold about their FND.  However, there needs to be 
more robust methods incorporated for the analysis and reporting of health belief outcomes.  
In addition, due to the lack of current treatment options, most participants had been living 
with their symptoms for some time with minimal support from healthcare providers.  This 
lack of established treatment pathways may contribute to the feelings of isolation participants 
report as a result of living with FND.  A more robust diagnosis process offering access to 
information around symptoms with the option of peer support may be beneficial for those 
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Appendix 2: Adapted Newcastle-Ottawa Scale  
 
Selection: (Maximum 5 star) 
 
1. Representativeness of the sample: 
a. Truly representative of people with FND. * (all subjects or random 
sampling) 
b. Somewhat representative of the average in the target group. * (non-
random sampling) 
c. Selected group of users/convenience sample. 
d. No description of the derivation of the included subjects. 
 
2. Sample size: 
a. Justified and satisfactory (including sample size calculation). * 
b. Not justified. 
c. No information provided 
 
3. Non-respondents: 
a. Proportion of target sample recruited attains pre-specified target or basic 
summary of non-respondent characteristics in sampling frame recorded. 
* 
b. Unsatisfactory recruitment rate, no summary data on non-respondents. 
c. No information provided 
 
4. Ascertainment of the exposure: 
a. Validated outcome measures. * 
b. Description of non-validated outcome measures.   
c. No details of outcome measures 
 
5. Version of IPQ outcome measure used in line with developer’s 
recommendations: 
a. Yes. * 
b. No 
 
Comparability: (Maximum 2 stars) 
 
1. Comparability of subjects in different outcome groups on the basis of design or 
analysis. Confounding factors controlled. 
a. Data/ results adjusted for relevant predictors/risk factors/confounders 
e.g. age, sex, time since vaccination, etc. ** 
b. Data/results not adjusted for all relevant confounders/risk 













Outcome: (Maximum 4 stars) 
 
1. Assessment of outcome: 
a. Independent blind assessment using objective validated laboratory 
methods. ** 
b. Unblinded assessment using objective validated laboratory methods. ** 
c. Used non-standard or non-validated laboratory methods with gold standard.  
* 
d. No description/non-standard laboratory methods used. 
 
2. Follow Up: 
a. yes if 3 months or longer* 
b. No if no follow up or < 3 months. 
 
3. Health Belief Reporting: 
a. Version of IPQ outcome dimensions reported in full * 
b. Version of IPQ Dimension partially reported 




Very Good Studies: 8-11 Stars 
Good Studies: 7-8 points 
Satisfactory Studies: 5-6 points 





























In line with recommendation from the Centre for Reviews and Dissemination that quality assessment tools are adapted to reflect the 
aims of systematic reviews, this scale has been modified from the Newcastle-Ottawa Quality Assessment Scale cross-sectional 
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Empirical Paper Abstract  
Introduction 
Lack of treatment options can impact negatively on the quality of life of those with Functional 
Neurological Disorders (FND). This study aimed to evaluate the efficacy, feasibility and 
acceptability of a brief intervention for routine care designed to address a gap in current service 
provision within NHS Grampian.  
Method 
A two session intervention session was developed. Outcomes collected included cognitive 
function, mood, quality of life and health beliefs; Healthcare utilisation and associated costs 
and patient experiential data. Twenty nine participants (20 female) completed baseline 
measures, 16 participants (10 female) attended the first group, differences between attenders 
and non-attenders were explored.  Eleven participants completed outcome measures over the 
four data timepoints.   
Results 
Psychological Measures Those attending the intervention  rated their physical health 
limitations as significantly less in addition to higher levels of perceived personal control than 
non-attenders. Those participating in the intervention reported significantly reduced fatigue at 
follow up. Understanding of FND improved post intervention and this increase in knowledge 
was maintained at follow up.  
Healthcare Utilisation and Costs: No differences between attenders and non-attenders.  63% 
of completers showed improved health status at follow-up on health-related quality of life.    
Patient Experience Measures: Participants reported the brief intervention met their 
expectations, subjective levels of self-report knowledge about FND increased significantly 
from pre to post intervention.   
Discussion 
The brief intervention showed promising results in the exploratory study in terms of efficacy, 
feasibility and acceptability.  Further research is required to ascertain if these findings are 
maintained in a larger sample. 
 
Key points  
Question: Is this brief group intervention feasible to address gaps in local service provision? 
Findings: Statistical differences were found between attenders and non-attenders in addition to 
those completing the brief intervention.  Importance: There may be utility in using health 
beliefs as a screening tool to identify those most of risk of non-attending; Increased knowledge 
of FND and improvements in health beliefs and quality of life were present 3 months after the 
intervention. Next Steps: To continue data collection in a larger sample and develop patient 
and clinician resources based on the content.  
 
Keywords 
Functional Neurological Disorder; brief intervention; psychological intervention; health beliefs; 









Functional Neurological Disorder (FND) refers to neurological symptoms that 
develop which have no known organic pathology, they are real and not imagined or 
feigned (Stone, Carson & Sharpe, 2005).  These symptoms can present in various ways 
and those living with FND may experience multiple symptoms which can be purely 
functional or there may be a functional overlay to co-morbid organic health conditions. 
For example, limb weakness, abnormal movement, non-epileptic seizures, cognitive 
and/or sensory problems.  The severity of symptoms found in FND is like other 
neurological conditions where symptoms can range from mild to severe with some 
patients being physically incapacitated as a result of the condition (Healthcare 
Improvement Scotland, [HIS] 2012).       
However, diagnosis can be difficult with healthcare professionals trained to 
diagnose and treat disease rather than symptoms (Stone et al., 2005).  As a result, if no 
disease is found there has been a suggestion historically, from healthcare professionals, 
that the symptom must not be real or the problem therefore must be psychological 
which is not  the case (Stone et al., 2005).  Messages to the brain from the body or from 
the body to the brain results in the symptoms the participants experience.  Neurologists 
make the diagnosis of FND based on positive signs.  For example, a person may 
present with limb weakness, reporting they have difficulty moving their leg when they 
try to carry out this movement, however when the person is asked to move their other 
leg the leg they have difficulty with reacts to the automatic reflex generated and 
responds as it should.  This reflex reaction is Hoovers sign, an example of one of the 
positive signs Neurologists use in diagnosing FND.  These positive signs indicate the 







not a structural problem within the nervous system.  However framing symptoms as a 
result of biopsychosocial factors is preferred to a purely psychological aetiology (Stone 
et al., 2005).  
It is estimated that one third of patients seen in Scottish neurology clinics have 
FND (Stone et al., 2005) making patients with FND one of the largest clinical groups 
accessing neurology services.  The volume of patients presenting with FND presents a 
significant challenge to the healthcare services.  Healthcare Improvement Scotland 
estimated the cost for the economy and healthcare service providers at £1.3 million for 
outpatient services, £6.01 million for inpatients and £4.01 million for primary care 
services (HIS, 2012). In addition, it is estimated that 27% of those with FND were not 
working due to their condition and are potentially more likely to be in receipt of state 
benefits creating significant financial demands on the state to fund and potential 
financial difficulties for those living with the condition (HIS, 2012). 
Unlike other neurological conditions less is known about FND and typically 
there is no set treatment pathway for health boards to follow.  This lack of treatment 
options to those with FND may start to change as clinical guidelines have begun to 
emerge.  Stepped care is a recommended model, in a number of conditions such as 
common mental health disorders e.g. depression; generalised anxiety disorder (GAD); 
panic disorder; obsessive-compulsive disorder (OCD); post-traumatic stress disorder 
(PTSD) in addition to simple phobias (Kendrick & Pilling, 2012). Stepped care 
treatment allows  patients to receive the level most effective for their difficulties at an 
appropriate level of resource, increasing the level of input when clinically required. A 
stepped care approach has been recommended as an appropriate model of treatment for 










 In the stepped care model proposed by HIS (2012) there are 3 broad steps for 
treatment which connect back into primary care community services; diagnosis and 
initial management; brief intervention and complex care.  In step 1 the importance of a 
robust diagnosis of FND by the clinician was recommended and augmented with high 
quality patient information. HIS (2012) recognised that clinicians varied in their skills 
and recommended access to continuous personal development (CPD) learning for 
clinicians.  
Step 2 aimed to meet the needs of patients with moderate physical disability and/or 
comorbid symptoms of mild/moderate anxiety/depression.  People meeting these 
criteria should have access to brief intervention programme based on the principles of 
cognitive behavioural therapy (HIS, 2012).  These services should be aiming to 
evaluate both the efficacy and cost effectiveness of these interventions (HIS, 2012).  
Patients requiring Step 3 were more likely to have severely levels of physical disability 
and/or complex mental health comorbidities (HIS, 2012).  Step 3 could be accessed 







directly if this was the level of input required or could be undertaken after steps 1 and 2 
are completed (HIS, 2012).  Allied health professionals at this level would be FND 
specialists assisting patients with managing their symptoms (HIS, 2012).   
The recommendations made by HIS (2012) were augmented in a report from the 
BPS Division of Neuropsychology (2013) who recognised that although the stepped 
care model proposed in the earlier work was helpful,  it lacked detail as to how patients 
would be matched to the level of care that best reflected their needs. The high personal 
costs to patients in terms of reduced physical function and quality of life due to clinical 
needs not being met effectively was also highlighted (BPS Division of 
Neuropsychology, 2013). The heterogenous pattern of difficulties those with FND 
require knowledgeable and trained staff (BPS Division of Neuropsychology, 2013; 
HIS, 2012).  A formulation-based approach was recommended, as was access to a 
centralised point of contact for both patients and clinicians who may be looking for 
appropriate information to assist patients with their diagnosis and access treatment 
processes which would be matched to the patients level of need (BPS Division of 
Neuropsychology, 2013). 
A more recent addition to the guidelines for clinician’s treating FND can be taken, 
indirectly, from new guidance for those working in non-specialist settings (National 
Institute for Health and Care Excellence [NICE], 2019).  Although not a guideline 
specifically for FND, it is acknowledged and listed as a potential explanation for 
conditions such as reoccurring dizziness, reoccurring limb and facial weakness, 
numbness/tingling, difficulties with word finding and problems with memory (NICE, 
2019). A further recommendation states that patients should be advised it is common in  







of potential comorbid conditions on the symptoms of FND is also highlighted for 
example, anxiety and cognitive problems such as memory and word finding difficulties 
(NICE, 2019).  It is recommended these difficulties are explored when assessing 
neurological conditions that are functional in nature (NICE, 2019).  
Taken together these recent guidelines provide the beginnings of a framework for 
clinical implementation.  There is a degree of overlap with their findings but a lack of 
clarity as to how these recommendations can be imbedded into clinical activity that can 
be managed within the limits of current resources. The importance the diagnosis 
process and patient information has been highlighted by guidelines as important, if this 
information is missing at diagnosis a stepped care model of care may be a suitable 
platform to provide this within a brief intervention (HIS, 2012).  Overall there appears 
to be a lack of consensus and direction from clinical guidelines with regards providing 
effective treatments for those with FND after diagnosis.  The interventions that are 
available are heterogenous and variables of interest vary widely with outcome measures 
for a study often being condition specific (BPS Division of Neuropsychology, 2013).  
For example with the primary outcome measure for interventions aimed at treating 
Non-Epileptic seizures focusing on the frequency of seizures (Barry, Wittenberg, 
Bullock, Michaels, Classen & Fisher, 2008; Baslet, Dworetzky, Perez, & Oser, 2015; 
Cope, Smith, King & Agrawal, 2017; Libbon, Gadbaw, Watson, Rothberg, Sillau et al., 
2019; Prigatano, Stonnington & Fischer, 2002; Rusch, Morris, Allen, & Lathorp, 2001; 
Zaroff, Myers, Barr, Luciano & Devinsky, 2017).  It may be more useful to explore the 
symptoms of FND using outcome measures that are more general in nature with a focus 







Cognition in FND 
Evidence about the importance of common comorbidities people with FND 
experience and ensuring these symptoms are considered when people present with 
neurological conditions that are potentially functional is starting to emerge (NICE, 
2019).  For example, many people frequently report co-morbid difficulties with 
cognition (Pennington, Newson, Hayre, & Coulthard, 2015).  A recent review identified 
the main issues those with FND present with are poor attention, memory and language 
difficulties, namely problems with word finding (Teodoro, Edwards & Issacs, 2018).  
Despite the prevalence of difficulties and new recommendations to assess cognitive 
symptoms from clinical guidelines very few studies include a cognitive assessment 
battery in their protocol (Teodoro et al., 2018). This omission is surprising considering 
a correlation between impaired cognition and symptoms of depression have been found 
in this population previously (Teodoro et al., 2018).  Cognitive difficulties have also 
been found to impact on quality of life for those with FND (Vechetova, Slovak, 
Kemlin, et al., 2018).  
Mood in FND 
Mental health difficulties are a frequent comorbidity in FND although it is 
common for those affected to contest referral to mental health services for treatment 
(Monzoni,  Duncan, Grunewald &  Reuber, 2011).  However, evaluating symptoms of 
depression has been undertaken with many different types of outcome measures.  For 
example studies have previously used the Hospital Anxiety and Depression Scale 
(HADS; Sharpe et al., 2011); The Depression Anxiety and Stress Scale (DASS-21; 
Barrett-Naylor, Gresswell & Dawson.,  2018);  Beck Depression Inventory (BDI; Barry 







al., 2017; Libbon et al., 2019) which makes it difficult to generalise effects not only 
across research but also across care settings.  Certain measures such as the HADS and 
the BDI are copyrighted for use which may exclude some services in the NHS having 
access to funds to pay for it in routine clinical practice.   
Health Beliefs in FND 
In addition to evidence about mood and cognition other common psychological 
constructs have been identified that can impact on the patient’s recovery from FND.   
The first of these are the beliefs patients attach to their symptoms to make sense of their 
experience.  The valence of health beliefs in FND has been identified as an important 
predictor of patient progress 12 months later (Sharpe, Stone, Hibberd, Warlow, 
Duncan., et al., 2010).  Furthermore, those with negative health beliefs have been found 
to be less reassured when test results are normal (Donkin, Ellis, Powell, Broadbent, 
Gamble & Petrie, 2005) which might hold consequences for healthcare care services.  
For example, if patients can not readily accept that there is nothing untoward found in 
the investigations, they may seek additional appointments with clinicians for 
reassurance or further investigations.  Negative health beliefs are common in those 
experiencing other illnesses with a functional basis such as chronic fatigue (Knoop, 
Prins, Moss-Morris & Bleeijenberg, 2010), fibromyalgia (Glattacker, Opiz & Jackel, 
2010) and irritable bowel syndrome (Rutter & Rutter, 2002).   
Health Related Quality of Life in FND 
Another psychological construct explored frequently in FND research is quality of 
life.  Quality of life is a difficult domain to define but is generally considered to be a 
multifaceted (Siegrist & Junge, 1989). Health-related quality of life (HRQoL) refers not 







have regarding the quality of their experience within the physical, mental and social 
domains of their life (Hays & Morales, 2001).  Function in HRQoL refers to the ability 
to perform activities of daily living such as personal care (e.g. washing and dressing), 
work (e.g. employment or household chores) and social function (interactions with 
friends and family members) (Hays & Morales, 2001).   
Those with FND often report a poor quality of life due to living with restricted 
physical function (BPS Division of Neuropsychology, 2013).  A high percentage of 
people find they must stop work due to the debilitating nature of their condition on their 
function resulting in many people with FND relying on state benefits (BPS Division of 
Neuropsychology, 2013).  Other symptoms found to negatively on HRQoL for those 
with FND include fatigue (Gelauff, Kingma, Kalkman et al., 2018; Vechetova, Slovak, 
Kemlink, Hanzlikova, Dusek et al., 2018) depression/anxiety, insomnia, pain and 
difficulties with cognition (Vechetova et al., 2018).   
There are many ways to measure HRQoL one of which is the utility 
measurement approach.   In this method a ‘utility’ is a value that can be derived from a 
current health state where ‘1’ is the best health imaginable and ‘0’ is equal to death 
(Sassi, 2006).  Life quantity can be measured in how many years there are between 
birth and death and the quality of life is ascertained at different timepoints between the 
endpoints of birth and death (Torrance, 1987). An important variable in ascertaining the 
balance between life expectancy, quality of life and treatment related costs is a unit of 
measurement called a quality-adjusted life-year (QALY). These units can be considered 
as being indicative of the “quality of a lifetime” (Torrance, 1987).    
QALY scores can be extracted from quality of life measures such as the Short 







underestimate QALY gains, therefore the recommended tool for conducting a cost 
utility analysis is the EuroQoL-5D (EQ-5D; Yang, Devlin & Luo, 2019).  The EQ-5D 
is also recommended by the National Institute for Health and Clinical Excellence 
(NICE) for calculating quality adjusted life years (QALYs) (NICE, 2008). The QALY 
is an index of the effectiveness of an intervention calculated by measuring the impact 
on life expectancy and quality of life of the patient compared to their current 
experience.  The QALY summarises the patients’ response on a standardised outcome 
measure that represents quality of life in several domains.  The length of time a patient 
has experienced the condition is used in the pre-treatment calculation and post 
intervention it is the length of time benefits from treatment are expected for that is used.    
For example, if a patient manages a condition for 5 years with no intervention and their 
current ratings result in a utility value of 0.8 the patient will have 4 QALYS (5 years x 
utility value of 0.8 = 4 QALYs).  If the patient, then accesses a new treatment and their 
ratings on the measure result in an increased utility value of 0.95 the patient will then 
have 4.75 QALYs (5 years x utility value of 0.95 = 4.75 QALYs).  As there has been an 
increase of 0.75 in the QALY post intervention, the intervention will be deemed to have 
a value of 0.75 QALYs over the no treatment option.   
Summary 
Quality of life experienced by those with FND may be negatively affected by 
the lack of treatment options after diagnosis. There are currently no FND specific 
treatments available within NHS Grampian after diagnosis.  This research project aims 
to evaluate delivering a brief two session intervention to ascertain if this would be a 







treatment option for people with FND within routine clinical practice in NHS 
Grampian. 
  The recommendations in the clinical guidelines produced to date for FND (BPS 
Division of Neuropsychology, 2013; HIS, 2012; NICE, 2019) have informed the 
psychological variables selected for this study.  These include cognitive function, 
mood, health beliefs and quality of life.   In addition to being recommended as domains 
being particularly relevant to FND, cognitive function, mood and health beliefs have all 
been found to impact negatively on quality of life for those with FND in previous 
research (Cope et al., 2017; Sharpe et al., 2010; 2011; Vechetova et al., 2018). The 
healthcare utilisation and a cost utility analysis informed the feasibility variables.  
Finally, this study will explore the expectations, knowledge and experience of those 
taking part in the intervention  
This research will allow a unique opportunity to explore potential differences 
between participants who attended and did not attend the intervention in addition to 
those who completed the programme.  The results from the outcome measures used in 
this feasibility project will be a chance to review the outcomes administered in the FND 
population which holds potential to inform outcome measures used as part of service 







Study Aims  
 This research aims to collect data over 4 timepoints.  Baseline (T1), Pre-Group 
(T2), Post-Group (T3) and 3 months after the group, Follow-Up (T4).   The research 
questions informing the current study are as follows: 
1. Did those attending the group differ significantly from non-attenders in their 
demographic, psychological or healthcare utilisation profile?  
2. What changes occurred in the standardised outcome measures indexing 
psychological constructs over the four timepoints, for those completing the 
group intervention?  
3. Did healthcare utilisation and healthcare costs vary for those attending the 
group intervention between T1 and T4?  
4. Did the experiential aspect of the group meet the expectations of those 
participating in the group intervention and were significant improvements 









Potential participants with FND were identified by the Consultant Clinical 
Neuropsychologist (FS) supervising the project from the departmental database at 
Aberdeen Royal Infirmary. This database was pre-existing and was not part of  this 
research, it is maintained by the Department of Clinical Neuropsychology.  It contained 
details of around 200 patients who had received a diagnosis of FND or were being seen 
and had a pre-existing diagnosis between November 2018 and April 2019 within the 
neurology service at NHS Grampian. The data for the database was input by an 
assistant psychologist from the Department of Clinical Neuropsychology from referral 
sheets received from the consultant neurologists.    Information included demographics 
such as age, gender, postcode; source of the referral to neurology; type of FND, 
whether it was pure FND or a functional overlay to another neurological condition; 
patient comorbidities; the other specialties the patient has accessed;  number of 
emergency consultation and admissions; number and type of radiology investigations; 
number of medications.  
Inclusion Criteria 
To ensure the participants were as close to patients that would be seen in routine 
clinical practice as possible, there was only one criterion for inclusion which was 
potential participants had to be aged between 18-64 years with a diagnosis of FND 









Exclusion criteria were as follows:   
1. Anyone the clinical neuropsychologist/neurologist felt, as a result of their 
clinical judgement, lacks capacity to consent. 
2. Anyone that was unable to understand the information sheet due to English not 
being their first language. This may be problematic as the information within the study 
relies on an understanding of written and spoken English. If knowledge of the English 
language is limited there would be a difficulty understanding the information being 
delivered. 
3. Severe sensory impairment. 
4. Anyone experiencing active severe psychiatric symptoms. 
5. A dependency on alcohol or recreational drugs.  
6. Learning disability as classified by ICD 10. 
7. Those unable to travel independently to attend group sessions due to the 
severity of their symptoms. 
Design 
This research was a feasibility study to develop future therapeutic options 
patients may have access to as part of a new care and treatment pathway within NHS 
Grampian.  Participants acted as their own control as baseline measures (T1) were 
collected depending when participants were seen, the T2 pre-group measures were 
completed at the start of the group intervention.  At the beginning of the appointment 
the participant information sheet was reviewed with the participant and an opportunity 







commitment of the study were discussed prior to informed consent being taken (see 
Appendix 2) the baseline outcome measures were then completed. 
Recruitment Procedure 
Prior to contacting patients from the database, the consultant clinical 
neuropsychologist reviewed the database for names for patients diagnosed with FND 
by consultant neurologists.  The consultant neurologist who originally referred the 
patient for inclusion on the database reviewed those patients as potential participants to 
ensure they were eligible to take part.  Invitation letters were prepared by the researcher 
which were signed by the consultant neurologist that had overseen the participants care 
and sent along with a participant information sheet, a reply sheet and a pre-paid 
envelope (See Appendix 3). If an individual was interested in the research, they notified 
this by returning a reply slip to the Department of Clinical Neuropsychology.   Potential 
participants were allocated an individual reference number to allow for information that 
was being returned could not be explicitly identified.    
On receipt of the reply sheet the researcher (PI) used the identification number 
to find the potential participants name and contacted them using telephone or email 
depending on the preference stated in the reply.  This initial contact gave the participant 
the opportunity to discuss the research and ask questions they may have had. If the 
person wished to take part in the research study a baseline appointment was arranged.  
In total, 29 baseline (T1) appointments were completed by the researcher (PI).  At 
baseline (T1) participants were given the opportunity to raise any questions they may 
have had regarding the study. Once the participant had no further questions or queries 







feasibility outcomes were then completed, more details about these are given later in 
this section.   
The Group Intervention 
Group Allocation  
 As a result of availability of an appropriate room and the field supervisor (FS) 
there were 4 groups available.  Group A and B were run on Tuesday morning and 
afternoon respectively, Group C was Wednesday morning with Group D on Wednesday 
afternoon.  Participants self-selected the group day and time that was most convenient 
for them to attend.  After baseline measures were completed 29 participants were 
distributed as follows over the four available group slots; [Group A (n=7); Group B 
(n=8); Group C (n=7); Group D (n=7)].   Attrition rates were high [45% (n=13)] 
between T1 and T2 resulting in a reduction in the number of people within the groups 
who attended the first session a further 19% (n=3) of those attending session 1 not 
attending session 2 (T3) two weeks later a further two individuals were lost to follow 
up resulting in 11 participants completing the intervention  [Group A (n=1); Group B 
(n=3); Group C (n=4); Group D (n=3)].  There were no differences in the format or 
content of the groups all participants received the same intervention content, delivered 
by the same facilitators in the same location.  
Group Design 
This brief intervention for FND in this feasibility study was comprised of two 
group sessions.  Sessions were split into two to minimise participant fatigue and allow 
an opportunity to reflect and consolidate the information presented.  The sessions lasted 
for 90 minutes and were spaced a fortnight apart.  The aims of the group were based on 







the context of predisposing, precipitating and perpetuating factor.  The concept of how 
biological and psychological factors potentially combined in FND was also introduced 
to explain why symptoms potentially occurred and why symptoms may fluctuate.   
The aims were to support participants to: 
1. Understand more about Functional Neurological Disorder.  
2. Develop knowledge about how physical and psychological processes interact in 
the body. 
3. Build knowledge of effective coping strategies.  
4. Develop awareness about things that can make symptoms worse. 
5. Gain awareness of resources and support available.  
6. Give participants opportunity to meet with others who have been through 
similar experiences. 
Group Resource Development  
Several resources utilised in the group intervention were developed specifically 
for the study by the researcher (PI) under the supervision of the consultant clinical 
neuropsychologist (FS) supervising the project within NHS Grampian.  
Group Content 
A formulation-based approach was used to frame FND from a biopsychosocial 
perspective.    PowerPoint slides for both sessions were developed and due to limited 
time, these were also printed to serve as participant handouts.  Flipcharts were used to 
facilitate discussion and capture information on common symptoms, potential triggers, 








The first session focused on what FND is and gave a basic overview of the 
central and peripheral nervous systems using a diagram presented on PowerPoint. 
Participants were given opportunity to discuss their thoughts around the complexity of 
the brain/body connection.  Common symptoms were explored, and the group was 
invited to discuss this.  Potential triggers for FND were then discussed giving the group 
chat opportunity to share their individual experiences.   
The second session content centred on living with FND included information 
regarding fatigue management, sleep, cognition, anxiety and depression and possibility 
of recovery.  These topics are transdiagnostic with other neurological conditions 
therefore the content of the FND group was based on similar groups run within the 
department of Clinical Neuropsychology in NHS Grampian for Acquired Brain Injury 
and Multiple Sclerosis.   
 Consultant Videos 
Bespoke videos for the study were developed by the researcher (PI) under the 
supervision of the field supervisor (FS) to augment the group content.   Two consultant 
neurologists working in NHS Grampian were invited to be recorded answering 
questions about FND.   Those attending baseline appointments for the group 
intervention also guided content from the questions and conversation held with the 
researcher (PI) during their session.   The video was shown in sections, the neurologists 
recorded content on what FND is, the diagnostic process, the likelihood of 
misdiagnosis, advice on living with FND and the chance of recovery.  
Filming was completed by the audio-visual department of the University of 







research was completed the videos were utilised as a source of information for patients 
receiving a diagnosis.  The videos can also be accessed from  a QR code in the health 
boards information leaflet and are also hosted on this website (see 
http://www.nhsgrampian.org/neurology/FND.html to access the videos and see a copy 
of the leaflet).  
Facilitator Guide  
A facilitator guide for the group was also developed.  The guide had 24 pages 
consisting of information about the group aims and background literature the 
intervention was based on.  The slides for both sessions were included with prompts 
regarding the key messages for each slide in order to assist consistency should the 
intervention be delivered in the future.   
Participant Feedback Questionnaires 
Two bespoke questionnaires were developed See Appendices 4 and 5  The first 
measured participants subjective changes in knowledge levels pre and post group. The 
second was more general and captured participants subjective experience of the group 
both in terms of content and delivery.   
Group Outcome Measures  
1. Demographic Information  
This included age, post-code, gender, marital status, years of education, 
symptom duration and age when symptoms began (see Appendix 6).  The Consultant 
Clinical Neuropsychologist (FS) provided categories to group types of symptoms based 
on the participants diagnosis, these were sensory, cognitive, motor, altered awareness 
and non-specific clinical presentations (see Appendix 7 for more information) . The 







provide an index of socioeconomic status. Demographic information was collected at 
baseline (T1) only.  
2. Cognitive Function: The Epitrak 
The Epitrak (Lutz & Helmstaedter, 2005) was utilised as a brief measure of 
cognitive function, it contains six subtests measuring response inhibition, visuo-motor 
speed, mental flexibility, visuo-motor planning, verbal fluency, and working memory. 
Administration time was around 15 minutes.  The total score is age corrected against a 
normative sample with higher scores indicative of a better performance and contains an 
indicator of clinical change as part of the scoring; the maximum score is 49 points. 
Scores between 29–31 points indicate mild impairment, Scores below 28 points are 
indicative of moderate impairment of cognitive function in these domains.  This 
measure has been found to have good reliability and criterion validity (Lutz & 
Helmstaedter, 2005). The EPI-Trak was administered at baseline (T1) and follow up 
(T4). 
3. Psychological Measures  
Standardised questionnaires indexing  symptoms of depression  (PHQ-9; 
Kroenke, Spitzer & Williams, 2001); anxiety (GAD-7; Spitzer, Kroenke & Williams, 
2006); health related quality of life (SF-36; Ware & Sherbourne, 1992), and health 
beliefs (IPQ-B; Broadbent, Petrie, Main & Weinman, 2006) were completed at 4 
timepoints.  These were prior to the intervention (baseline, T1) at the start of the 1
st
 
group session (pre-group, T2).  The third time point was immediately after the 
intervention (post group, T3), the fourth and final timepoint was 3 months after the 







Mood: Depression PHQ-9 
Symptoms of depression were assessed using the Patient Health Questionnaire 9 
(PHQ-9; Kroenke et al., 2001).  Nine items assess experience of depressive symptoms 
over the previous 14 days, ranging from not at all to nearly every day, total score ranges 
from 0-27 with higher scores indicating more severe depressive symptoms.  Scoring 5, 
10, 15, and 20 categorises depressive symptoms into mild, moderate, moderately severe 
and severe respectively. This measure has been shown previously to have good validity 
and reliability (Kroenke et al, 2001).  
Mood: Anxiety GAD-7 
Anxiety symptoms were measured using Generalized Anxiety Disorder (GAD-
7; Spitzer et al., 2006).  This measure has 7 items with 4 options measuring levels of 
anxiety over the previous 14 days ranging from not at all to nearly every day with 
scores ranging from 0-12 with cut-offs of 5, 10, and 15 representing cut-off scores for 
mild, moderate, and severe anxiety, respectively. The measure has good reliability and 
validity (Spitzer et al., 2006). 
Both the PHQ-9 and GAD-7 have been used to assess levels of depression and 
anxiety in participants with functional neurological disorders taking part in group 
psychological interventions previously (Cope et al., 2017; Libbon, et al., 2019). Both 
measures are self-report based on the participant’s perception of symptoms experienced 
over the previous 14 days, rating whether they experience difficulties nearly every day 
to not all. Both measures are recommended by The National Institute for Health and 







Health Related Quality of Life SF-36 
  The SF-36 (Ware & Sherbourne, 1992) consists of 36 items with between 2 and 
6 responses to select from, each item has a minimum score of 0 and a maximum score 
of 100. 35 of the individual items are grouped together to give 8 subscales: physical 
function (10 items), physical health limitations (4 items),  emotional health limitations 
(3 items),  energy/fatigue (4 items), emotional wellbeing (5 items), social function (2 
items), pain (2 items) and general health (5 items). Subscales are scored by adding the 
scores of all items within the subscale together and dividing by the number of items in 
the subscale to get a mean score for each domain with higher scores indicating a higher 
quality of life (Ware & Sherbourne, 1992). The SF36 has previously been found to 
show good criterion validity and high internal reliability (Jenkinson, Wright and 
Coulter, 1994), it has also been used in populations with FND previously (see Pick et 
al., 2020 for a review). The SF-36 was completed in the current study at T1, T2, T3 and 
T4.  
Health Beliefs: IPQ-B 
The Brief Illness Perception Questionnaire (IPQ-B) has been found to show 
good validity and reliability (Broadbent et al.,  2006).  The IPQ-B has been utilised in 
assessing the health beliefs of people with functional neurological disorders in previous 
group psychological interventions (Cope et al., 2017; Libbon et al., 2019).  This 
measure of health beliefs has nine items and is based on components of the Self-
Regulation Model (SRM) (Leventhal et al., 1980; 1984) and assessed both cognitive 
and emotional representations patients had about their FND.  The IPQ-B contains 5 
items on cognitive factors included in illness perception including:  consequences (item 







(item 5). Illness concern (item 6) is the perception of both cognitive and emotional 
beliefs.  The scale contains 2 emotional items; coherence (item 7) and emotional 
representation (item 8). Participants rate each item on a 0–10 scale. The last item in the 
brief IPQ allows participants to identify factors they believe are causal in the 
development of their FND symptoms for categorical analysis.    Levels of threat 
perceived by the participant can be calculated by reversing the scores from item 
numbers 3, 4 and 7 and adding to other items. Higher score indicates higher perceived 
threat with a minimum threat level of 0 and a maximum level of 80. The IPQ-B was 
administered at T1, T2, T3 and T4 of the study. 
4. Healthcare Utilisation and Costs Measurement –  
These outcomes were included to build an understanding of the frequency patients 
with FND accessed health care services allowing calculation of the associated costs.  
Health Care Utilisation was collated using the Client Service Receipt Inventory; 
(Chisholm, Knapp, Knudsen, Amaddeo, Gaite, et al., 2000)  
Healthcare Utilisation: The Customer Services Receipt Inventory 
The Customer Services Receipt Inventory (CSRI) was utilised as a measure of 
healthcare use over the previous 3 months.  The CSRI has been found previously to 
offer a standardised and adaptable measure that can be individualised for the population 
being studied (Chisholm et al., 2000).    In the current study the CSRI included 
healthcare utilisation in three health sectors; Community care, Elective care and Non-
Elective Care.  The community care category recorded the number of contacts 
participants had with their GP and/or practice nurses; the number of repeat 
prescriptions was also collated.    Elective care included outpatient appointments with 







included pre-arranged hospital contacts as an overnight case, an outpatient and/or a day 
patient, finally non-elective care provision use was measured.   Further information 
regarding medication, formal support from the NHS/Social Work and informal support 
from friends and family as well as employment, sick leave, earnings and state benefits 
accessed. The CSRI has been used as a measure of healthcare utilisation for people 
with FND previously (Goldstein, Chalder, Chigwedere, Khondoker, Moriarty, et al., 
2010).  
HRQoL Cost Utility Analysis: EQ-5D 
The EQ-5D is a 2-part self-report questionnaire with 2 components; a 
descriptive system to calculate health state and a visual analogue scale (VAS) 
(Herdman, Gudex, & Lloyd et al.. 2011).   The health state component has five 
categories: mobility, self-care, usual activities, pain/discomfort and anxiety/depression 
with 5 options to choose from: no problems, slight problems, moderate problems, 
severe problems and extreme problems, these options are scored from 1-5 respectively 
with higher numbers reflective of greater impairment. Health state responses are 
indicated by ticking the most relevant of the 5 options, the score from each option is 
compiled into a 5-digit number representing the health state which is converted into a 
utility value (quality of life).  The utility value can fall between 0 (Dead) and 1 (Perfect 
Health) and can be calculated for people in the UK using a calculator available from the 
website of the EQ-5D developers  
(see https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-
sets/crosswalk-index-value-calculator/.  The quality adjusted life years (QALY) is 
derived from the utility value by multiplying it with the number of years a person has 







patients with functional disorders previously in a physiotherapy treatment programme 
(Nielsen, Ricciardi, Demartini, Hunter, Joyce, & Edwards., 2015) and is the 
recommended by NICE as the instrument of choice for QALY generation (NICE, 
2008).  
  The VAS in the EQ-5D is labelled ‘The best health you can imagine’ at the top 
of the scale and ‘The worst health you can imagine’ at the bottom. Best health has a 
maximum score of 100 with worst health minimum scoring is 0. A mark is placed on 
the scale and the corresponding number written in the box alongside. The EQ-5D was 
administered at baseline (T1) and follow up (T4). 
5. Experiential Measures – At end of the group and at follow up people were 
encouraged to feedback their experience of taking part in the group intervention by 
completing bespoke questionnaires to capture this feedback.   
Participant Knowledge 
Those attending their first group session were invited to self-report the 
following using a five-point Likert scale (see Appendix 4) 
1. their current levels of knowledge levels what they thought FND is,  
2. the process of how FND was diagnosed;  
3. how much they knew about how physical & psychological processes interact in 
the body 
4.  what they knew about effective coping strategies;  
5. Knowledge levels on what made symptoms get worse;  what they knew about 







Participants rated their knowledge levels on a 5-point Likert scale with options 
ranging from ‘I know nothing’ to ‘I know a lot’.  Participants chose the box they best 
felt reflected their current knowledge level for each area and indicated how helpful they 
thought meeting others with FND would be. This exercise was repeated after the 
delivery of the group.  
Participant Experience 
At the end of the second session, participants were also given the opportunity to 
complete anonymous generic feedback on the workshop (See Appendix 5).  The items 
covered how acceptable the group intervention was to those taking part in terms of the 
number of sessions, their duration, what was included and length of time between the 
sessions.  Participants were also asked to rate their thoughts on the quality of the 
location and group facilitation.  Additional questions gave opportunity for participants 
to feedback their thoughts on what they liked or would change about the content.  
Finally, participants were asked if they would recommend the group to a friend with 
FND if it were available. The study matrix provides a summary of all the measures and 
the time points these were administered during the study  (see Table 1).  All outcome 








                                                                                                                                        
Table 1 Study matrix table of measures and administration timepoint  






















ethics (IRAS and 
University) 
NHSG R&D Approval * 
    
Develop Group materials *     
Informed consent  *    
DEMOGRAPHICS  *    
COGNITIVE FUNCTION 
Epi-Trak   *   * 
PSYCHOLOGICAL MEASURES     
Mood: Anxiety 
Generalised Anxiety 
Disorder 7 (GAD 7) 
 * * * * 
Mood: Depression 
Patient Health 
Questionnaire 9 (PHQ-9) 
 * * * * 
Quality of Life 
Short Form health Survey 
(SF-36) 
 * * * * 
Health Beliefs      
Brief Illness Perception 
Questionnaire (IPQ-B) 
 * * * * 
FEASABILITY MEASURES 
    
Healthcare Utilisation 
Client Services Receipt 
Inventory (CSRI) 
 *   * 
Cost Utility Analysis 
EuroQoL-5D (EQ5D) 
 *   * 
EXPERIENTIAL MEASURES     
Patient Knowledge    * *  







Ethical Approval  
A favourable ethical opinion was granted by NHS North of Scotland Research 
Ethics Service (REC Reference 18/NS/0137; Approved 17 January 2019; See Appendix 
10). The research was also registered with the NHSG Research & Development Office 
receiving management permission to proceed locally with the research (R&D 
Reference 2018PC011; Approved 19 January 2019; See Appendix 11). 
Statistical Analysis 
Data Screening  
Statistical analysis was undertaken using IBM Statistical Package for Social 
Sciences version 24. Data was explored in line with the recommendations given in 
Field (2005) to establish the distribution of the data in order to ensure it met criteria for 
using parametric tests in analysis. All variables in the standard measures met 
assumptions for parametric analysis except the SF36 subscale for physical limitations 
for Pre-group (T2) only which was positively skewed (Zskewness >2.58; Field, 2005).  
This variable was transformed using the square root transformation in SPSS 24 to 
restore normality (Zskewness = 2.00; Field 2005) prior to analysis.  
In order to establish if duration of symptoms correlated with psychological 
outcomes Pearson’s correlations were undertaken (see Appendix 1).  There were no 
significant correlations detected between the potential covariant and cognitive function 
(Epi-Trak), depression symptoms (PHQ-9); symptoms of anxiety (GAD-7); subscales 
of measures tapping health beliefs (IPQ-Brief) and HRQoL (SF-36)  as a result 









Boxplots were used to visually inspect the data for outliers. Z scores for each of 
the dependent variables for the standard measures were calculated using SPSS in order 
to screen for potential outliers. The critical value to establish if a participant could be 
considered an outlier was a z-score that was either less than -3.29 or greater than +3.29.  
This critical value was adopted as it would be unlikely data that were normally 
distributed would fall out with this limit (Field, 2005). Identifying the cause of outliers 
is not a straightforward process in clinical research, and there has been debate on data 
sets ought to be managed. Consequently, researchers have been encouraged to apply 
their own judgement as to whether outliers are removed or included in data (Osborne 
and Overbay, 2004).  
Data Analysis: Attenders and Non-Attenders 
If a participant completed base line measures and attended the first group 
session they were categorised as an attender.  Those completing baseline measures but 
not attending the first session were categorised as a non-attender.  Analysis for study 
aim 1 which explored differences between attenders (n=16) and non-attenders (n=13) 
on continuous demographic variables were conducted using independent samples t-
tests. As sample sizes were small, categorical variables in the demographic information 
were analysed using a Fishers Exact test.  Independent samples t-tests were also used to 
compare attenders and non-attenders on psychological outcome measures.   
Due to some healthcare providers being accessed only once or not accessed at 
all, data from the Client Services Receipt Inventory were collapsed across provider 
representing healthcare utilisation within community, elective and non-elective care 
providers.  The new variables provide a summary of the total number of contacts for 







tests were used to explore if contact levels differed between attenders from non-
attenders.        
Experiential measures were not completed by non-attenders therefore it was not 
possible to explore differences regarding experience of the group.   
Data Analysis: Completers 
Due to the brief nature of the intervention, a completer was classified as 
participant who completed measures at baseline (T1), pre-group (T2) and Post-Group 
(T3) and follow up (T4) at 3 months. Due the small sample size and the number of 
participants within each group [Group A (n=1); Group B (n=3); Group C (n=4); Group 
D (n=3)] data were collapsed across groups (n=11) for all analyses.  
Data for study aim 2 (psychological measures) were analysed using a repeated 
measures ANOVA, Bonferroni adjustments were used for pairwise comparison.   
Paired sample t-tests were used to analysis changes for study aim 3 (healthcare 
utilisation) and study aim 4 (patient experience) outcomes. 
A reliability analysis was carried out on the participant knowledge questionnaire 
created specifically for the FND brief intervention.  A Cronbach’s alpha (over .7 
represents a high internal consistency.  The six items assessing knowledge levels 










Recruitment began in February 2019 (see Figure 1 for flow of participants). 187 
patients were identified by a consultant clinical neuropsychologist using the FND 
Database managed by the Department of Clinical Neuropsychology based in NHS 
Grampian.  The Consultant neurologists aligned to the patient was contacted to review 
if the patient met study criteria prior to being invited to take part.  As a result of the 
neurologists’ review 35 patients were felt not to meet study criteria an additional 53 
identified patients were not progressed within the study due to not receiving 
confirmation from their neurologist that they were eligible to invite.  In total 98 letters 
of invitation were sent out to eligible patients in April 2019 
There were 55 reply sheets received between April and August 2019.   77% of 
respondents (n=42) wished to participate in the research, 69% (n=29) completed 
baseline measures.  These baseline appointments lasted approximately 60 minutes and 
were undertaken between June until September 2019 one morning a week within NHS 
Grampian.  19% (n=8) did not attend the baseline appointment, 5% (n=2) did not 
respond to contact following up their reply sheet and 7% (n=3) were not eligible. Of the 
participants who were ineligible two were hospitalised for psychiatric conditions during 
the recruitment window and one person revealed they were receiving treatment for an 

















  Not all of those completing baseline measures (T1) attended the group 
intervention.  The attrition rate between completing baseline and attending the first 
group session (T2) was 45% (n=13). with a further 19% (n=3) of those attending 
session 1 not attending session 2 (T3) two weeks later.  85% (n=11) of participants 
completing the group attended the follow up session in February 2020, 3 months post 
group (T4).    The mean timescale from baseline to session 1 was 91.19 days (SD 31.38 
days).  No reasons were given for not attending by those leaving the research.    
Participants 
A total of 29 people completed baseline measures with 13 of those not attending 
the first group session. There were two different analyses conducted, the first included 
all participants who attended the baseline appointed and completed T1 measures.  This 
analysis compared those participants who attended the first group session to those who 
did not.  The second analysis included only those participants that completed T1, T2, 
T3 and T4 measures there by completing the group intervention and returning 3-month 
post group follow up.    
Study Aim 1 
The first aim of the current study was to explore if there were significant 
differences between attenders and non-attenders in demographic, psychological and 
healthcare utilisation profiles.  
Demographic Information 
The demographic information of all participants completing baseline (T1) 
measures can be seen in Table 2.  There was no significant difference between 








Table 2 Demographic profile analysis for Attenders and Non-Attenders 
 All Participants Attenders Non-Attenders Independent 
Samples t-test 
(df=27) 
 M SD Min-Max M SD Min-Max M SD Min- 
Max 
t p 
Age in years  46.34 (12.30) 21 - 77 47.88 13.750 25 - 77 44.46 10.47 21-58 -.74 .47 
Age symptoms began  39.73 (14.76) 07 - 75 41.29 17.69 7 - 75 37.23 10.72 20-54 -.63 .53 
Symptom duration 
(months) 
86.31 (123.62) 12 – 492 83.81 150.93 12 - 492 89.00 87.73 12-240 .11 .91 







Study Aim 1 Demographic profiles Attenders and Non-Attenders    
Variables in Table 3 are represented by frequency data for all participants as 
well as attenders and non-attenders. The postcode provided by the participant allowed 
calculation of local area deprivation using the Scottish Index of Multiple Deprivation 
(SIMD) database to provide a measure of socioeconomic status.   SIMD quintiles were 
used where SIMD quintile 1 has most deprivation and SIMD quintile 5 has the least 
deprivation.   
Fishers Exact test was used for statistical analysis of these frequency variables 
as a result of the expected counts being less than 5 in the statistical comparisons of the 
frequencies.   No statistical differences were found between those attending or not 
attending the group intervention on any of the analyses suggesting these variables were 









Table 3  Demographic frequency data for gender, marital status, SIMD Quintile and 
Geographical Locality, and employment status for all participants, group attenders and 
non-attenders. 
 











Gender (%) 20 Female (68.9%) 
9 Male (31.1%) 
10 Female (62.35%) 
6 Male (37.5%) 
10 Female (76.9%) 
3 Male (23.10%) 
0.45 
Marital Status (%)   0.92 
Married 17 (58.60% 10 (62.50%) 7 (53.8%)  
Single 8 (27.60%) 4 (25.00%) 4 (30.8%)  
Widowed 3 (10.30%) 2 (12.00%) 1 (7.7%)  
Divorced/Separated 1 (3.40%) 0 1 (7.7%)  
SIMD (%)  
1=Most Deprived 
5 = Least Deprived 
   0.87 
SIMD Area 1 2 (6.90%) 0 2 (15.40%)  
SIMD Area 2 6 (20.70%) 4 (25.00%) 2 (15.40%)  
SIMD Area 3 9 (31.00%) 4 (25.00%) 5 (38.50%)  
SIMD Area 4 6 (20.70%) 3 (18.80%) 3 (23.10%)  
SIMD Area 5 6 (20.70%) 5 (31.20%) 1 (7.70%)  
Locality (%)    0.57 
Aberdeen City 12 (41.40%) 5 (31.25%) 7 (53.80%)  
Aberdeenshire 9 (31.38%) 8 (50.00%) 1 (7.70%)  
Moray 8 (27.60%) 3 (18.75%) 5 (38.50%)  
Employment  
Status (%) 
   0.46 
Full Time Work 6 (20.70%) 2 (12.50%) 4 (30.80%)  
Part-Time Work 6 (20.70%) 2 (12.50%) 4 (30.80%)  
Retired 3 (10.30%) 2 (12.50%) 1 (7.70%)  
Not Working (Health) 10 (34.50%) 7 (43.80%) 3 (23.10%)  







FND results in symptoms that are like disorders that have a structural or 
neurodegenerative cause, but the mechanism for people with FND is different.  All 
participants had a diagnosis of FND from a consultant neurologist.  For the purposes of 
this analysis the categories formulated by the Consultant Clinical Neuropsychologist 
were used to assess primary presenting FND symptom of participants (see Table 4).   
 
















    0.22 
Altered Awareness 5 (17.20%) 4 (25%) 1 (7.70%)  
Motor 7 (24.10%) 4 (25%) 3 (23.05%)  
Non-Specific 3 (10.40%) 0 3 (23.05%)  
Sensory 14 (48.30%) 8 (50%) 6 (46.20%)  
1
 Attenders & Non attenders 
 Comparisons between the type of FND symptom experienced by patients 
attending and not attending the group were conducted and no significant differences 
were detected using Fishers exact test (p=0.22) which can be interpreted as the main 
type of FND symptom the participant presented with did not determine  whether they  








Psychological Measures: Attenders and Non-Attenders 
Psychological outcome measures collected at T1 were analysed to determine if 
there were significant differences between attenders and non-attenders (see Table 5).  
  Cognitive Function: Epitrak  
There were no significant differences between attenders and non-attenders 
found in the cognitive domain [t(26)= -.81; p = 0.42];  However, using Epitrak cut off 
scores to interpret the results showed participants would be categorised differently.   
Attenders (M=32.07) scored in the average range for overall performance whereas non-
attenders fell into the mildly impaired category (M=30.08).  
Mood: Depression PHQ-9 & Anxiety GAD-7 
There were no significant differences found for depression, t(27) = -.93; p=0.36; 
or anxiety t(27) =-.63; p=0.54 between attenders and non-attenders.  Interpreting the 
PHQ-9 scores in line with the clinical cut off scores showed both attenders (M=14.50) 
and non-attenders (M= 12.08) would be categorised as having moderately severe levels 
of depression.  For anxiety as indexed by the GAD-7 respectively both attenders 
(M=10.06) and non-attenders (M=8.46) fell into the moderate category.   
Quality of Life: SF36  
Significant differences were found between attenders (M=21.87) and non-
attenders (M=1.92) in the psychological domain of quality of life (SF-36) on the 
physical health limitations subscale.  An independent samples t-test revealed that those 
not attending the group reported higher scores on the limitations to physical health 
subscale of the SF36 (16.4) = -2.21, p<0.05.  This can be interpreted as attenders report 







who scored lower on this subscale reflecting greater feelings of being limited as a result 
of physical health.   
As the results from the other subscales did not reveal any significant differences 
(see table 5) this would suggest that attenders and non-attenders experienced a similar 
quality of life in other areas of their health-as indexed by the SF-36.  
Health Beliefs: IPQ-B  
There were significant differences between attenders (M=4.50) and non-
attenders (M=2.23) with regards their self -reported levels on the IPQ-Brief personal 
control subscale.  An independent t-test showed that those attending the group reported 
higher levels of control over their FND symptoms than those who did not attend t (27) 
= -2.34, p<0.05. No other subscales differed significantly on the IPQ-B measure 
between attenders and non-attenders suggesting both types of participants help similar 







Table 5  Descriptive and inferential statistics for psychological outcome measures for those attending and not attending  













M SD Min- 
Max 
t df p 
Cognition Overall Score EPITRAK (age corrected) 32.07 6.20 17–42 30.08 6.77 19-39 -.81 26 0.42 
Mood PHQ9 Depression 14.50 7.81 3–27 12.08 5.87 2–23 -.93 27 0.36 
GAD7 Anxiety 10.06 6.70 2-21 8.46 7.02 1–21 -.63 27 0.54 
Quality of 
Life 
SF36 Physical Functioning 42.50 31.20 0-100 53.08 29.05 5-95 .94 27 0.36 
SF36 Physical health Limitations 21.87 35.21 0-100 1.92 6.93 0-25 -2.21 16.4 0.04 
SF36 Mental Health Limitations 39.56 45.91 0-100 56.46 47.90 0-100 .97 27 0.34 
SF36 Energy/Fatigue 26.56 20.31 0-85 30.00 16.07 15-75 .49 27 0.62 
SF36 Emotional Well Being 52.00 27.90 4-88 61.53 20.75 28-92 1.02 27 0.32 
SF36 Social Functioning 41.56 31.89 0-100 47.38 26.56 0-100 .53 27 0.60 
SF36 Pain 41.31 25.55 0-100 47.31 32.31 0-100 .56 27 0.58 
SF36 General Health 38.75 16.78 10-70 33.07 18.77 0-65 -.86 27 0.39 
Health Beliefs IPQ-Brief Consequences 6.75 2.69 0-10 6.61 1.75 4-10 -.15 27 0.88 
IPQ-Brief Timeline 8.44 1.86 5-10 8.53 2.06 5-10 .14 27 0.89 
IPQ-Brief Personal Control 4.50 3.01 0-10 2.23 1.96 0-5 -2.34 27 0.02 
IPQ-Brief Treatment Control 4.87 3.38 0-10 2.77 2.55 0-7 -1.85 27 0.07 
IPQ-Brief Identity 7.12 2.41 1-10 7.31 1.55 5-10 .24 27 0.82 
IPQ-Brief Illness Concern 5.81 3.20 0-10 6.92 2.10 3-10 1.07 27 0.29 
IPQ-Brief Coherence 3.69 3.20 0-10 4.54 2.92 1-10 .79 27 0.43 
IPQ-Brief Emotional Representation 6.12 3.36 0-10 6.08 2.50 2-10 -0.4 27 0.96 







 Healthcare Utilisation: Attenders and Non-Attenders    
Services accessed by both attenders and non-attenders are reported at baseline 
in Table 6.   In order to contextualise the different levels of healthcare participants 
would typically access, health sectors were divided into three sectors; Community care 
which comprised to GP and practice nurse appointments in primary care;  Elective care 
which was comprised of specialisms regularly accessed by those with FND (e.g. 
Neurology, psychology, psychiatry and allied health professionals such as occupational 
therapy and physiotherapy.  Outpatient, day patient and overnight stays were also 
detailed in the health sector.  Non-elective care included visits to A+E; non-elective 
overnight admissions and treatment in intensive care.   
Participants were asked to self-report their contact with these healthcare 
providers during the 3 months prior to their baseline appointment, responses were 
collected using the Client Services Receipt Inventory (see Table 6).   Independent 
samples t-test revealed there were no significant differences between the total number 
of times attenders (M=4.75; SD =2.86) and non-attenders (M=3.56; SD = 3.47) 
accessed community care services 3 months prior to baseline; t (15) = -.77; p =.45. 
Analysis on the total number of times elective care service were showed no differences 
between contact levels of attenders (n= 12; M=5.50; SD=3.15) and non-attenders (n=8; 
M=4.00; SD = 3.12) for the elective care sector; t(18) = -.99; p= .34.   No comparative 
analysis was completed for non-elective services due to only 1 person accessing non-

































Health Sector Provider Attenders  Non-Attenders 
n % Count M SD  n % Count M SD 
Community Care GP  7 24% 28 4.00 2.16  8 27% 31 3.88 3.56 
Practice Nurse 4 14% 10 2.50 2.38  1 4% 1 1.00 n/a 
Elective Care 
 
Neurology 2 7% 2 1.00 0.00  4 14% 5 1.25 .50 
Psychology 3 10% 11 3.67 2.08  0 0% 0 n/a n/a 
Psychiatry 1 4% 8 8.00 n/a  3 10% 5 1.67 1.15 
Physiotherapy 4 14% 21 5.25 4.99  2 7% 9 4.50 2.12 
Occupational Therapy 2 7% 5 2.50 0.71  3 10% 3 1.00 .00 
Other 4 14% 11 1.25 0.74  4 14% 4 1.00 .00 
Elective Overnight stay 2 7% 3 1.50 0.71  0 0% 0 n/a n/a 
Outpatient at Hospital 4 14% 7 1.25 0.50  1 4% 2 2.00 n/a 
Day patient at Hospital 1 4% 1 1.00 n/a  2 7% 2 1.00 1.00 
Non-Elective  
Care 
Accident and Emergency 2 7% 2 1.00 1.00  1 4% 1 1.00 n/a 
Non-Elective Overnight Stay 1 4% 1 1.00 n/a  0 0% 0 n/a n/a 
Intensive Care 0 0% 0 n/a n/a  0 0% 0 n/a n/a 







The unit and total costs of these patient contacts are reported in Table 7.  As 
there were no significant differences between attenders and non-attenders in their 
healthcare utilisation costs are collapsed across attenders and non-attenders.  In addition 
to the number of patients accessing the different health sectors, the number of times the 
service was accessed (count) was also detailed along with associated descriptive 
statistics.  Costs used in Table 7 were taken from Public health Scotland cost books for 
NHS Scotland (https://www.isdscotland.org/Health-Topics/Finance/Costs/Detailed-
Tables/Speciality-Costs/).   
Community care costs were 17% of the total healthcare accessed, hospital based 
elective care services made up 80% of the cost total and non-elective emergency care 
was accessed by 10% of participants (£591), no participants accessed intensive care 
treatment.  In total 29 participants with a diagnosis of FND accessed healthcare services 







Table 7 Healthcare costs based on responses from the 29 participants completing the Client Services Receipt Inventory at baseline (T1)  
 
 
Health Sector Health Care Provider 
Number 
Accessing 
Baseline Service Access 
(Previous 3 months) 














£ n % Count Mean SD Min Max 
Community Care 
GP Contact 15 51% 59 3.93 2.89 1 12 70 4,130 275 




Neurology 6 21% 7 1.17 0.41 1 2 80 1,680 280 
Psychology 3 10% 11 3.67 2.08 2 6 97 1,067 355 
Psychiatry 4 14% 13 3.25 3.30 1 8 85 1,105 276 
Physiotherapy 6 21% 30 5.00 4.00 1 12 30 900 150 
Occupational Therapy 5 17% 8 1.60 0.89 1 3 86 688 138 
Elective Overnight Case
a
 2 7% 3 1.50 0.71 1 2 4,272 12,816 6408 
Outpatient at Hospital
b
 5 18% 7 1.40 0.55 1 2 230 1,610 322 
Day patient at hospital
c
 3 10% 3 1.00 0.00 1 1 332 996 332 
Non-Elective Care 
Accident and Emergency 3 10% 3 1.00 0.00 1 1 197 591 197 
Non-Elective Overnight Stay 1 4% 1 1.00 n/a 1 1 166 166 166 
Intensive Care 0 0% n/a n/a n/a n/a n/a - - - 
 Totals - - 156 - - - - - 26,222 452 
*
Other services category deleted as unable to provide cost information 
a
 Individual specialities not captured cost reflects generic gross cost per case for elective inpatient for NHSG from Public Health Scotland book R044X
 
b
 Individual specialities not captured cost reflects generic speciality outpatient gross cost for NHSG from Public Health Scotland book R044X 
c







HRQoL EQ-5D-5L: Attenders and Non-Attenders 
 As non-attenders did not complete the group intervention, data from the EQ-5D-
5L was only collected at baseline (T1). As there was no comparison data, it was not 
possible to calculate difference in quality adjusted life years. However, the data were 
analysed to explore if there were significant differences in the pattern of responses 
between attenders and non-attenders for the HRQoL dimensions in the EQ-5D-5L.   
Participants chose the response that best reflected their health in five quality of 
life domains, on the day the questionnaire was completed.   A summary of the 
distribution of frequency data for the EQ-5D-5L dimensions for both attenders and non-
attenders at baseline (T1) are shown in Table 8. Fishers Exact test was used to analyse 
the frequency counts of the responses on the EQ-5D-5L due to low expected counts in 
the comparisons.  No statistical differences were found between those attending or not 
attending the group intervention which suggested that none of the dimensions in the 
EQ-5D-5L included were related to whether the participant attended the intervention or 
not.   
 The mean of the EQ-visual analogue scale (EQ-VAS) scores where the 
participant rated their health on the day between 0 is worst health imaginable and 100 is 
the best health imaginable. for both attenders and non-attenders were analysed using an 
independent samples t-test.   No significant differences were found between the VAS 
ratings for attenders (M=57.25; SD =23.11) and non-attenders (M=63.08; SD = 15.48) 









Table 8 EQ-5D-5L frequencies and percentage reported by dimension and level for 







































Mobility (%)   0.71 
1 No problems – 5 Unable to walk   
Level 1 4 (25%) 4 (31%)  
Level 2 5 (31%) 6 (47%)  
Level 3 5 (31%) 3 (22%)  
Level 4 2 (13%) 0  (0%)  
Level 5 0  (0%) 0  (0%)  
Self-Care (%)   0.28 
1 No problems – 5 Unable to wash/dress   
Level 1 5 (31%) 6 (47%)  
Level 2 9 (57%) 5 (38%)  
Level 3 0 (0%) 2 (15%)  
Level 4 1 (6%) 0  (0%)  
Level 5 1 (6%) 0  (0%)  
Usual Activities (%)  
1= No problems – 5 Unable to do usual activities 
 0.87 
Level 1 3 (19%) 2 (15%)  
Level 2 6 (37%) 5 (38%)  
Level 3 4 (25%) 5 (38%)  
Level 4 1 (6%) 1 (9%)  
Level 5 2 (13%) 0 (0%)  
Pain Discomfort   0.38 
1 No pain – 5 Extreme Pain    
Level 1 1 (6%) 3 (22%)  
Level 2 5 (31%) 1 (9%)  
Level 3 7 (44%) 6 (47%)  
Level 4 3 (19%) 3 (22%)  
Level 5 0 (0%) 0  (0%)  
Anxiety/Depression   1.00 
1 Not anxious/depressed – 5 Extremely Anxious/depressed  
Level 1 6 (37%) 6 (47%)  
Level 2 4 (25%) 3 (22%)  
Level 3 3 (19%) 3 (22%)  
Level 4 2 (13%) 1 (9%)  







Study Aim 2 
The second aim of the study was to identify what changes occurred in the 
standardised outcome measures indexing psychological constructs, for those 
completing the group intervention.  
Group Completers Psychological Outcome Measures 
Cognitive Function: Epitrak  
A  repeated measures ANOVA showed that the level of performance for  
cognitive function, as indexed by the Epitrak, remained unchanged for completers 
between T1 (M=33.20) and T4 (M=32.70) with no significant differences found; [F 
(1,9) = 0.12; p= 0.73]. This result suggested participants cognitive profile did not 
change significantly between baseline and follow up.   
Mood: Depression PHQ-9 & GAD-7 
A repeated measures ANOVA was conducted to explore symptoms of 
depression and anxiety across the four time points, which showed no changes in scores 
as indexed by the PHQ9 [F (3, 30) = 2.42; p = 0.86] or GAD7 ; [F(3, 30) = 1.01; p = 
0.40]. (See Error! Reference source not found.9)  
Quality of Life: SF36  
The energy/fatigue subscale of the SF-36, showed a significant improvement for 
completers at T4 (see Error! Reference source not found.9). A repeated measures 
ANOVA indicated that scores for the energy/fatigue subscale differed across the four 
data timepoints, F(3,27) = 3.22 p<0.05. Inspection of pairwise comparisons revealed 
that post-group scores (T3; M=14.00) differed significantly from follow up (T4; 
M=30.00) p <0.05 with completers reporting higher levels of energy/lower levels of 







subscale suggest that although there were no significant differences during the 
intervention phase fatigue levels were reported as significantly less between the 
intervention ending and follow up.   
Health Beliefs: IPQ-B 
The repeated measures ANOVA for the coherence subscale on the IPQ-B (see 
Error! Reference source not found.9).  revealed significant revealed that scores for 
the coherence subscale differed significantly across the four study time points, F(3, 30) 
= 5.67; p<0.00.   Inspection of pairwise comparisons revealed that the pre-intervention 
scores [Baseline (T1; M= 4) and Pre-group (T2; M=4)] did not differ significantly. 
There were also no significant differences between post-intervention scores [Post-
Group (T3; M= 7.36) and Follow up (T4; M=6.27)].  However, there were significant 
differences between pre and post intervention scores with significant differences 
between T1 and T3 (p <0.01) also T1 and T4 (p <0.05).  T2 scores differed 
significantly with T3 (p<0.01) and T4 (P<0.05). The results found in the IPQ-B 
coherence subscale suggest that participants rated their understanding of their illness 
highest immediately after the group at T3 and this increase in understanding was still 















T1 T2 T3 T4 Repeated Measures ANOVA 
M  SD M SD M  SD M SD F  df Sig  
Cognition Overall Score EPITRAK (age corrected) 33.20 5.18 Not Administered 32.70 7.08 0.12 1, 9 0.73  
Mood 
PHQ9 Depression 16.27 7.32 17.27 7.95 15.64 6.8 13.45 6.44 2.42 3, 30 0.86  
GAD7 Anxiety 10.73 6.97 11.00 7.54 11.18 7.45 8.73 6.67 1.01 3, 30 0.40  
Quality of 
Life 
SF36 Physical Functioning 42.50 32.34 61.50 34.88 63.50 35.67 52.00 35.21 1.41 3, 27 0.26  
SF36 Physical Health Limitations 15.00 33.75 5.00 10.54 17.50 28.99 20.00 32.91 0.79 3, 27 0.51  
SF36 Mental Health Limitations 30.00 48.30 33.33 47.14 50.00 52.70 50.00 45.13 1.95 3, 27 0.18  
SF36 Energy/Fatigue 19.00 13.08 18.75 17.92 14.00 19.83 30.00 23.57 3.22 3, 27 0.04  
SF36 Emotional Well Being 47.60 28.00 45.50 29.29 38.40 30.18 51.60 26.83 0.98 3, 27 0.42  
SF36 Social Functioning 32.60 27.10 31.25 27.80 27.50 22.67 43.85 21.29 2.50 3, 27 0.81  
SF36 Pain 35.90 23.24 26.75 23.04 35.00 29.11 37.50 26.33 2.71 3, 27 0.06  
SF36 General Health 37.50 18.45 31.00 21.45 24.5 20.88 33.5 20.42 1.58 3, 27 0.22  
Health Beliefs 
IPQ-Brief Consequences 7.64 1.80 7.55 1.81 7.45 2.11 6.91 1.87 0.81 3,30 0.50  
IPQ-Brief Timeline 9.00 1.41 8.82 1.66 8.27 2.10 8.73 1.85 1.14 3,30 0.35  
IPQ-Brief Personal Control 4.18 3.12 3.73 2.76 4.82 2.52 3.73 2.33 0.61 3,30 0.61  
IPQ-Brief Treatment Control 4.09 3.56 3.36 2.94 4.09 3.11 3.36 2.87 0.39 3, 30 0.75  
IPQ-Brief Identity 7.91 1.58 7.55 1.92 8.09 1.04 7.64 1.91 0.48 3, 30 0.70  
IPQ-Brief Illness Concern 6.73 2.72 6.91 2.63 6.64 2.87 6.09 2.43 0.58 3,30 0.63  
IPQ-Brief Coherence 4.00 3.29 4.00 2.61 7.36 1.21 6.27 3.04 5.67 3,30 0.00  
IPQ-Brief Emotional Representation 6.73 2.87 6.73 3.04 6.73 3.10 6.82 3.06 0.12 3, 30 0.99  







Study Aim 3 
The third aim of this research compared the healthcare utilisation and associated 
healthcare costs for those attending the group intervention between T1 and T4.   
Group Completers Healthcare Utilisation: CSRI 
Services accessed by completers at both baseline (T1) and follow up (T4) are 
reported in Table 10.   Health sectors were, as previously, divided into three sectors; 
Community care (GP and practice nurse appointments in primary care); Elective care 
(e.g. Neurology, psychology, psychiatry and allied health professionals.  Outpatient, 
day patient and overnight stay) and Non-elective care included (A+E; non-elective 
overnight admissions and intensive care).  Completers self-reported their contact with 
each healthcare providers during the 3 months prior to their baseline appointment, and 
3 months prior to their follow up appointment.   
 A paired sample t-test revealed there were no significant differences between 
the total number of times completers accessed community care health services 3 
months prior to baseline (T1)  (M=7.12; SD =5.81) and follow up (T4)  (M=3.62; SD = 
3.20); t (7) = 1.61; p =.15. No significant differences were found for number of elective 
healthcare contacts at T1 (n= 7; M=6.86; SD=3.13) and T4 (n=7; M=7.57; SD = 7.82); 
t(6) = -0.25; p= .81. Paired samples t-tests revealed no significant differences between 
non-elective care contacts at baseline (n=2;M=1.50) and follow-up (T4) (n=2; 
M=2.00); t(1) = 1; p=.50.  
The unit and total costs of healthcare contacts for completers are reported in 
table 11.   There was a reduction of costs related to community and elective care.  






























Health Sector Provider Completers T1  Completers T4 
n % Count M SD  n % Count M SD 
Community Care GP 5 45 24 4.80 1.92  6 54 21 3.50 1.76 
Practice Nurse 3 27 9 3.00 3.07  7 64 11 1.57 0.79 
Elective Care 
 
Neurology 1 9 1 1.00 n/a  1 9 1 1.00 n/a 
Psychology 3 27 11 3.67 2.08  1 9 4 4.00 n/a 
Psychiatry 1 9 8 8.00 n/a  2 18 9 4.50 4.95 
Physiotherapy 2 18 14 7.00 7.14  2 18 10 5.00 1.41 
Occupational Therapy 2 18 5 2.50 0.71  2 18 5 2.50 2.12 
Other 2 18 3 1.50 0.71  4 36 11 2.75 0.96 
Elective Overnight stay 2 18 3 1.50 0.71  0 0 0 n/a n/a 
Outpatient at Hospital 2 18 2 1.00 0.00  3 27 10 3.33 3.21 
Day patient at Hospital 1 9 1 1.00 n/a  0 0 0 n/a n/a 
Non-Elective  
Care 
Accident and Emergency 2 18 2 1.00 0.00  2 18 2 1.00 0.00 
Non-Elective Overnight Stay 1 9 1 1.00 n/a  2 18 2 1.00 0.00 
Intensive Care 0 0 0 n/a n/a  0 0 0 n/a n/a 







 Table 11 Healthcare costs comparison at T1 and T4 for those completing the intervention  
 













n n% Count 
Total cost 
(count x  
unit cost 
n n% Count 
Total cost 
£ 
(count x  
unit cost 
Community Care 
GP Contact 70 5 45 24 1,680 6 54 21 1,470 -210 
-124 
Practice Nurse 43 3 27 9 387 7 64 11 473 86 
Elective Care* 
Neurology 80 1 9 1 80 1 9 1 80 0 
-12,022 
Psychology 97 3 27 11 1,067 1 9 4 388 -679 
Psychiatry 85 1 9 8 680 2 18 9 765 85 
Physiotherapy 30 2 18 14 420 2 18 10 300 -120 
Occupational Therapy 86 2 18 5 430 2 18 5 430 0 
Elective Overnight Casea 4,272 2 18 3 12,816 0 0 0 0 -12, 816 
Outpatient at Hospitalb 230 2 18 2 460 3 27 10 2,300 1,840 
Day patient at hospitalc 332 1 9 1 332 0 0 0 0 -332 
Non-Elective Care 
Accident and Emergency 197 2 18 2 394 2 18 2 394 0 
166 Non-Elective Overnight Stay 166 1 9 1 166 2 18 2 332 166 
Intensive Care 0 0 0 0 n/a 0 0 0 0 0 
 Totals - - - 81 - - - 75 - -11,980 -11, 980 
*
Other services category deleted as unable to provide cost information 
a




 Individual specialities not captured cost reflects generic speciality outpatient gross cost for NHSG from Public Health Scotland book R044X 
c











Group Completers HRQoL Cost Utility Analysis: EQ-5D-5L  
The frequency data at baseline (T1) and follow up (T4) were analysed to 
explore if there were differences in the pattern of responses given by group completers 
at T4 compared to T1 (see Table 12).   At domain level, the number of participants 
experiencing problems reduced over for mobility, self-care and usual activities.  There 
were no changes in the number of people reporting problems for the domains of 
pain/discomfort and anxiety/depression.  However, the pattern of data from T4 from T1 
did highlight that there were changes at participant level occurring on the dimensions of 
the EQ-5D-5L.  For example, at T4 no participants were reporting symptoms at Level 5 
whereas at T1 level 5 scores were reported for self-care usual activities and 
anxiety/depression.   
In order to explore changes at participant level more fully, the changes in the 
distribution of the domain levels for each participant were calculated using the Paretian 
classification of health change (see Devlin, Parkin & Browne, 2010).  The T4 and T1 
health profiles were considered using four possible outcomes (See Table 13) 
1. There was no change in health profile at T4 from T1 as indexed by the EQ-5D-
5L 
2. T4 health profile is better than T1 indicating health as improved according to 
the EQ-5D-5L 
3. The T4 health profile is poorer than T1 indicating poorer health at follow up as 
measured by the EQ-5D-5L.   
4. It is not possible to compare the health profiles at T4 and T1, further 
information would be required prior to categorising changes as an being 







  Table 12 EQ-5D-5L frequencies and percentage reported by dimension and level for group completers at baseline (T1)  
and follow up (T4) 
 









































Level 1 3 28% 4 36% 3 27% 5 46% 0 0% 1 9% 0 0% 0 0% 4 36% 4 36% 
Level 2 4 36% 3 28% 6 55% 4 36% 5 45% 6 55% 4 36% 3 27% 3 27% 3 27% 
Level 3 2 18% 1 9% 0 0% 1 9% 4 36% 3 27% 5 45% 5 46% 2 18% 2 18% 
Level 4 2 18% 3 27% 1 9% 1 9% 0 0% 1 9% 2 18% 3 27% 1 9% 2 18% 
Level 5 0 0% 0 0% 1 9% 0 0% 2 18% 0 0% 0 0% 0 0% 1 9% 0 0% 
Total 11 100% 11 100% 11 100% 11 100% 11 100% 11 100% 11 100% 11 100% 11 100% 11 100% 
Number reporting 
some problems 
8 (73%) 7 (64%) 8 (73%) 6 (55%) 11 (100%) 10 (91%) 11 (100%) 11 (100%) 7 (64%) 7 (64%) 
Change in number 
reporting problems 




Table 13 Changes in health at participant level from baseline (T1) to Follow up (T4) for the EQ-5D-5L dimensions as categorised by the 











No change 0 0 0 0 0 1 
Improved 1 4 5 2 5 7 
Worse 1 0 1 1 2 3 
Mixed Change 0 0 0 0 0 0 









Seven patients reported improvements in their overall health profile at T4 
compared to T1.  The greatest improvements were seen in usual activities (n=5), 
anxiety and depression (n=5) and self-care (n=4), pain (n=2) and mobility (n=1) were 
also reported as improved at T4 by participants.  Three participants rated their health 
state as poorer at T4.  Mood (n=2), (mobility (n=1), usual activities (n=1) and 
pain/discomfort (n=1) showing higher ratings at T4 than T1.  One participant recorded 
no change in scores on the EQ-5D-5L from T1 to T4.   
Due to the small number of people completing the intervention, there was an 
insufficient number of completers (n=11) to allow utility values to be calculated for the 
EQ-5D-5L.  This means it was not possible to calculate differences in quality adjusted 
life years for this current intervention at this time. However, the pattern of results noted 
in the measure suggests the EQ-5D-5L can be successfully administered in this 
population.    
 A paired samples t-test was used to explore if the scores on the EQ-visual 
analogue scale (EQ-VAS) at T4 differed from T1 for those participants completing the 
intervention.  No significant differences were found between T4  (M=55.09; SD 







Study Aim 4 
The final aim of the study looked at the experience of the participants to 
determine if the experiential aspect of the group met their expectations and significantly 
improve the subjective levels of knowledge about FND post intervention.  
Group Completers Experiential Measures  
Expectations of the participants 
Full details of the expectation’s participants reported about taking part in the 
group can be found in Appendix 8.  The following themes were found within the 
participant pre-group expectations (see Table 14) 
Table 14 Theme of participant expectations for the group intervention 




Most participants hoped to increase their knowledge on FND and meet others 
with the condition to share and learn from each other’s experiences.  In addition to 
learning how to manage symptoms, it was important for some of those attending to help 
not only others receiving a diagnosis but also to help educate healthcare professionals.  
To help those working with people with FND to be more empathic to the condition in 
order to reduce patients potentially feeling ‘fobbed off’ (see patient 2 comments in 
Appendix 9)  
  
 Theme of Expectation N 
(max = 11) 
 Increase knowledge of FND 10 
 Access peer support 8 
 Managing symptoms 5 
 Informing future healthcare for both 








Subjective Knowledge of Completers 
 Significant differences were found for all knowledge objectives between T2 
(Pre) and T3 (Post) group (see Table 15).  Paired samples t-test revealed that 
participants rated their knowledge on what FND is higher at T3 (M=4.38) than T2 (M = 
3.46); t (12) = -3.49; p <0.00.  Knowledge on how FND was diagnosed also increased 
significantly for completers between T2 (M=2.92) and T3 (M=4.08); t (12) = -4.21; p 
<0.00.  Understanding of how physical and psychological processes interact in their 
body was rated as higher at T3 (M=4.15) than T2 (M=3.54); t(12)= -2.31; p<0.05.   It 
was reported more was known about coping strategies at T3 (M=4.31) than T2 
(M=3.08); t (12) = -3.12, p=<0.01. Participants reported they knew more about what 
made their symptoms worse at T3 (M=4.46) than T2 (M=3.46); t (12) = -2.94, p <0.01.   
Knowledge on useful resources also increased significantly between T2 (M=2.54) and 
T3 (M=4.23); t(12) = -5.50, p<0.00.  There were no significant difference found, t (12) 
=-0.94, p=0.37 between T2 (M= 4.62) and T3 (M=4.92) on how helpful it  would be to 
meet others  as  there was a ceiling effect with the majority of participants rating they 























What FND is 3.46 0.97 2-5 4.38 .51 4-5 -3.49 .00 
Diagnosing FND 2.92 1.04 1-5 4.08 .64 3-5 -4.21 .00 
How Physical & Psychological Process 
interact in the body 
3.54 0.88 2-5 4.15 .69 3-5 -2.31 .04 
Coping Strategies 3.08 1.32 1-5 4.31 .48 4-5 -3.12 .01 
Why symptoms get worse 3.46 1.27 1-5 4.46 .52 4-5 -2.94 .01 
What resources are available 2.54 0.97 1-4 4.23 .60 3-5 -5.50 .00 










Figure 3 Participant evaluation of group intervention sessions  
Experience of the intervention  
 At the end of the second group, participants were invited to complete an 
anonymous group evaluation form with space to leave comments if desired (See 
appendix 9 for summary of qualitative comments).  85% of participants (n=11) opted to 
do see figure 3.   
With regards the session length, 4 participants felt the sessions could be slightly 
longer at 2 hours rather than the 1.5 hour in the study.  This extra time was felt to allow 
more time for questions and group discussion. 45% (n=5) felt there could be an 
additional session to consolidate info and give opportunity to meet the others again to 
learn from each other.   27% (n=3) participants stated a preference for the sessions to be 








All participants felt the range of topics and the amount of information presented 
on each one was about right.  One participant felt more time could be spent on each 
topic, another felt there was a lot to take in.  The volume of information was reiterated 
by another participant who felt that weekly sessions over 4-6 weeks would give 
participants more time to consolidate information and discuss with the group the 
following week.   
All participants found the room suitable and the group facilitators approachable 
(see figure 4).   One participant noted the helpfulness of the neurologist’s information 
videos and the relaxed atmosphere in the session. Although everyone found the group 
information accessible a few participants stated concerns about their ability to 
remember the information later due to the difficulties they were experiencing with their 
memory at the time of the group.   




















The elements of the intervention participants particularly liked were the friendly 
atmosphere and having a mix of peers and professionals.  One participant reflected they 
felt the group normalised FND and brought awareness to the fact that some healthcare 
professionals do not know much about it. Changes that were suggested mainly included 
more time for peer discussion and some more time to digest the information. All of 
those completing the group would recommend it to a friend. Further comments were 
related to knowing more about FND and taking away the feeling of being alone after 
diagnosis. Signposting to other resources was also considered helpful.  There was also 
mention that the group might be helpful to families supporting those with FND and not 









This purpose of this research was to develop a brief intervention and evaluate 
the its feasibility  in supporting people with FND within NHS Grampian.  This study 
aims to address a current gap in local service provision.    Data were collected over four 
timepoints; baseline (T1), pre-group (T2), post-group (T3) and 3 months after the 
group, follow-up (T4).    
There were no significant differences in demographic variables between 
attenders and non-attenders.  Significant differences were found for psychological 
outcomes with those choosing not to attend the first session rating their physical health 
limitations as significantly greater than those who attended.  In addition non-attenders 
reported lower levels of perceived personal control than attenders.    Follow up data 
revealed those completing the group reported significantly reduced fatigue at follow up.  
In addition 63% of completers reported improved health status at follow-up on health-
related quality of life..  Subjective levels of self-report knowledge about FND increased 
significantly from pre to post intervention.   Although their understanding of FND was 
reported highest post intervention this increased knowledge level remained in follow up 
data. Some participants thought two sessions was enough  but with some preferring 
some more, thoughts around duration were also mixed.   However the topics included 
and amount of information was about right. Participants found the information was 
easy to remember and felt comfortable with the room and the facilitators.   
In the current study, there was an attrition rate of 45% (n=13) for participants 







an identical rate of non-attendance found in a one to one treatment programme for FND 
previously (Demartini, Batla, Petrochilos, Fisher, Edwards et al., 2014).  
Demographic variables in the current research were compared and revealed no 
significant differences between attenders and non-attenders.   The high prevalence of 
females in the study match gender and age profiles of people with FND found 
previously (see Carson & Lehn, 2016; Edwards & Bhatia, 2012 for reviews).  This is 
the first study to have included a measure of health inequalities in an FND population 
taking part in a therapeutic intervention.   Although no significant differences were 
found in the distribution of participants across the SIMD quintiles, the majority of 
participants resided in the higher socio-economic areas.  These figures should be 
interpreted in the context  of location with this finding likely to  have reflected the 
lower distribution of people living in these locations within the Grampian area as a 
whole rather than being an indication of health inequalities within the study sample 
The analysis of data measuring psychological constructs showed mixed results.  
There were no significant differences between types of participant for the cognitive task 
or for either measures of mood. However, non-attenders reported significantly lower 
levels of personal control at baseline than those who went on to attend the intervention.  
Those not attending the intervention also rated themselves as being significantly more 
limited in their life by physical health.   
The personal control subscale within the IPQ-Brief has been previously found 
to correlate with a measure of self-efficacy and as a result,  may be a proxy indicator 
for health beliefs indexed by this subscale (Broadbent et al., 2006).  Health beliefs are 
formed and maintained by the ongoing appraisal of symptoms and how successfully 







Interpreting the finding that non-attenders perceive low personal control and feel highly 
limited physically would suggest that a lack of confidence in personal ability to manage 
symptoms becomes a self-fulfilling prophecy which goes on to affect physical function 
resulting in a lower quality of life.  A comparable pattern of results has been found 
using similar measures in a population with chronic pain previously (de Rooji, DeBoer, 
van deer Leeden, Steultjens & Dekker, 2014).   
In previous research, perceived levels of  personal control have been associated 
with an anticipation that the proposed treatment would not be effective (van Wilgen, 
van Ittersum, Kaptein, & van Wijhe, 2008).  A non-significant trend in the current data 
potentially supported this finding in the current data set with the treatment control 
subscale of the IPQ-brief also being reported lower by non-attenders than attenders.  
This  suggested that participants who did not take part were more likely to believe the 
intervention would not help to manage their symptoms.  Although this difference 
between the attenders and non-attenders on the treatment control subscale did not reach 
significance, the probability value approached a level of significance which suggested 
the result may be attributable to insufficient power in the study.  
 To maximise engagement with interventions there needs to be an awareness of 
how best to  address maladaptive beliefs that participants with FND may have that 
could lead to self-imposed barriers to accessing treatment.  Those with FND have 
shown evidence of bias in their thinking previously by deciding on the likelihood of a 
particular outcome long before all the information was available for evaluation (Pareés, 
Kassavetis, Saifee, Sadnicka, Bhatia, et al., 2012).  This cognitive bias in the context of 
health beliefs may indicate that some people with FND update their mental model of 







their symptoms (Pareés et al., 2012) which may subsequently link to impact negatively 
on their beliefs about their ability to cope.     
The current  intervention was facilitated by a Consultant Clinical 
Neuropsychologist and a trainee psychologist.  The link the current intervention had 
with mental health may potentially contributed to non-attendance.  There is  historical 
evidence to suggest that engaging with mental health services can be problematic for 
people with FND. A lack of engagement may be as a result of experiencing feelings of 
stigma after being diagnosed with FND (Rommelfanger, Factor, LaRoche, Rosen, 
Young & Rapaport, 2017).  Receiving information  that psychological factors can 
explain the physical symptoms being experienced may be difficult to reconcile 
(Rommelfanger et al., 2017). The processing of the diagnostic label of illness and the 
meaning a person extracts from this has been identified as important in the self-
regulation model of health beliefs  (Leventhal et al.,  1980; 1984).   
There were no significant differences in the healthcare utilisation patterns 
between attenders and non-attenders in the current data.  However, current results add 
to evidence that the health care utilisation  of people with FND involved a high number 
of services being accessed on a regular basis. It is important to interpret these findings 
with caution as these figures were self-report and not corroborated with health records 
to verify accuracy.  As a result these figures may be an under representation of clinical 
contacts.  This result  showed primary care were the most frequently used services by 
those with FND in the current sample.   
Due to only completing baseline data it was not possible to conduct quality 
adjusted life years for attenders and no-attenders.  There were no significant differences 







over the 5 levels of quality of life or for quality of life reported on the visual analogue 
scale.   
Previous research has included an attempt  to differentiate between those 
attending or not attending an FND therapeutic intervention previously (Goldstein et al.,  
2004).  The previous research comparison was limited as it focused  on demographic 
and symptom profiles only and did not include a statistical analysis (Goldstein et al., 
2004).  The current research is the first to widen the comparison.  Inferential statistics 
were used to explore demographic, psychological and healthcare utilisation variables to 
ascertain if there were significant differences between those with FND  who attended 
and did not attend the group intervention.   
The second aim considered potential changes in psychological measures for 
those completing the group intervention over the four data collection timepoints of the 
intervention.  No significant differences were found for cognitive performance, 
participants fell into the average performance range and this was stable between 
baseline and follow up.  This result suggests there may be inconsistencies between 
objective and subjective experience of patients with FND regarding their cognitive 
abilities.  This is the first study to have included a measure of cognitive function in the 
evaluation of a psychological intervention.  Although there is limited research on the 
cognitive profile of those with FND, existing research has interpreted the discrepancy 
between subjective cognitive performance and objective measures may reflect a lack of 
attention capacity (Teodoro et al., 2018).  Attentional resources may be utilised with 
internal monitoring of bodily symptoms in addition to dealing with pain and fatigue 








A strength of the current study was the collection of data over four time points.  
The inclusion of a baseline and follow up period allowed natural fluctuations over time 
to be included rather than focusing in on pre and post measures only which would have 
been over a short duration of 2 weeks.   Scores on the mood measures also did not 
change significantly over the four data collection time points, however, there appeared 
to be a natural fluctuation of symptoms over time. The symptoms of depression and 
anxiety are accommodated by the SRM of health beliefs which suggests that these 
symptoms are the by-product of symptoms continuing despite attempts to manage them  
(Leventhal et al., 2007).   
There were significant differences found in the quality of life measure with the 
subscale of energy/fatigue significantly improved from post group.  This was 
interesting as this occurred despite no change in cognition, mood, areas that have been 
found to impact on quality of life for those with FND previously (Vechetova et al., 
2018).   This may reflect the benefit of allowing a period of consolidation in therapeutic 
interventions to allow participants time to incorporate techniques in their daily routine.   
In addition, there were significant improvements in the health belief measure for 
illness understanding (coherence).  The significant difference found post group 
remained significant at 3 month follow up.  Cope et al., (2017) also found 
improvements on the coherence subscale  for their brief intervention, however they did 
not include a follow up period and their sample included only patients with Functional 
non-epileptic attacks.  The current study extends these findings to a mixed FND 









Healthcare utilisation and healthcare costs were also explored for those 
completing the group intervention.   No significant difference was found in the number  
of healthcare contacts between  T1 and T4.  Care should be taken when interpreting this 
finding as the data are based on subjective self-report  which has not been verified with 
health records.   
Healthcare utilisation and healthcare costs were also explored for those 
completing the group intervention.  Similar to findings between attenders and non-
attenders there were no significant findings from the number of contacts at T1 and T4 
however similar to the analysis of attender and non-attenders the data analysed was 
self-reported and not verified with health records which could result in an under 
reporting of contacts.     
Although limited numbers meant  QALY’s were unable to be calculated for the 
current intervention, the data from the EQ-5D-5L showed that some of the participants 
moved from having problems to no problems on the mobility, self-care and usual 
activities dimensions.  In addition, improvement in overall health state was reported by 
63% of the completers. This is an encouraging result from this exploratory work and 
fits with the findings of lower fatigue and increased illness coherence reported earlier 
from the psychological measures.    In order to explore the robustness of this finding a 
larger sample would be required than is in the current study. Seven patients reported 
improvements in their overall health profile at T4 compared to T1.   
Measures of subjective participant knowledge of FND  and a questionnaire 
capturing the participants experience of the group were included in order to gain 
feedback to inform future versions of the intervention.  Results showed that participants 







and help inform future healthcare for patients and healthcare providers. They felt the 
group helped them meet these expectations.   Subjective levels of knowledge about 
FND increased significantly between pre and post group for all study aims.   
Constructing a narrative from the additional comments it became apparent that  the 
group format addressed feeling isolation meaning participants felt validated and less 
alone.  This feeling of isolation is common in those with FND (Nettleton, Watt, 
O’Malley & Duffey, 2004).  Reduced isolation as a result of meeting others has been 
found in previous group interventions exploring patient feedback previously (Cope et 
al., 2017; Blake, Ablitt, Ruffman, Morley, William et al., 2019). It was encouraging to 
see that participants were unanimous in rating the topics included as acceptable with 
the amount of information.  The current study based the intervention on a 
biopsychosocial model allowing a holistic approach to be taken rather than positioning 
symptoms as a result of an arbitrary physical/mental health dichotomy when trying to 
explain the diagnosis.   
The use of video commentary from the neurologists was also  received well.  
Developing this resource may have increased the validation felt by participants and it 
addressed concerns such as misdiagnosis.  Many of the participants had voiced 
concerns around the FND diagnosis and had interpreted the process of as reflecting 
uncertainty around the diagnosis rather than as a corroboration of patterns that relate to 
a functional disorder.   This highlighted the current methods of diagnosis by elimination 
that may contribute to the high healthcare utilisation patterns seen in the FND 
population.    Session length and number of sessions were indecisive with some 
thinking 2 was enough some preferring some more, some felt timing between session 







Participants found the information was easy to remember and felt comfortable with the 
room and the facilitators.   
Strengths and Limitations 
The current research showed several strengths in the methodology. 
Incorporating an analysis between attenders and non-attenders allowed a comparison of 
these participants on a range of data.  There were potential differences identified around 
health beliefs and quality of life revealed from this analysis.   A wide range of outcome 
measures based on relevant clinical guidelines were completed with a mix of   FND 
subtypes which allowed generalisation across the wider FND population.  Including a 
baseline and follow up period allowed results to be considered over a longer temporal 
duration.  Follow up data showed that effects found in participants appear to sustain 
post intervention.   
This research was innovative and well received by NHS staff and those with 
FND.   There was a lot of interest from other disciplines regarding when the 
intervention would be clinically available in order for them to be able to refer patients 
for treatment.   The intervention was well supported within the neurology department 
who were keen to support recruitment. It is hoped that the intervention will be 
integrated into a clinical pathway for FND in time.  It is also being considered for 
modification so it can be used as the basis for a transdiagnostic intervention for other 
functional disorders such as IBS and fibromyalgia.        
The study resulted in resources being developed;  Two of the neurologists 
contributed by agreeing to be filmed talking about FND.  This has resulted in patient 
information media for those receiving a diagnosis which can be accessed on NHS 







part with benefits in health beliefs and quality of life emerging from only two sessions, 
although care has to be taken in attributing these differences to the intervention as there 
is no comparison group.    
The high attrition rate and small sample size are obvious limitations.  However 
numbers in both these areas are in line with similar research.  In research it is common 
for an intervention to have a team of people working on it.  In this study there was one 
person [the researcher (PI) ] responsible for coordinating all recruitment contacts, 
administration, completing all the baseline appointments, inputting and analysing the 
data.  There were different lengths of time that people may have had to wait before the 
group started.  Potentially symptoms may have improved and the person decided not to 
attend, alternatively they may have deteriorated and people felt too unwell.   As this 
was a research project it was not possible to contact patients to ask their reasons for 
non-attendance. Future research would add to the data collected in the feasibility 
project which may augment the benefits seen in participants to date. Some feedback 
highlighted that there was some difficulty in participants’ ability to remember the 
information later due to cognitive difficulties.  Developing patient resources based on 
the group content and format would address this limitation of the  study.   
Future research 
The current study did not have a comparison group, randomised control trials 
(RCT) are considered the ‘gold standard’ when evaluating interventions.  The efficacy 
of a brief intervention for FND may benefit from the RCT design, however matching 
the heterogeneity of participants within the FND population may be challenging.  
Future research would also benefit from running the intervention on a larger scale in 







completing assessment and allow groups to be run sooner after baseline.  A larger study 
to explore if the changes seen within the outcome measures in the feasibility study are 
retained would be beneficial.  This would allow opportunity to collect further data on 
health beliefs and quality of life to explore if there is a predictive utility regarding who 
is likely to attend based on the  personal control and physical health limitation 
questions.  Running a larger study would also allow more data for the EQ-5D and allow 
QALY adjusted life years to be calculated  to inform cost effectiveness of the group 
intervention.   
Significant differences between attenders and non-attenders were detected in the 
domains of health beliefs and quality of life, suggesting that those not attending were 
less confident in their ability to manage their condition, feeling more physically 
restricted.  There may also have been a belief that the intervention may not be suitable.  
No significant differences between access to healthcare sectors summary costs, 
however there was evidence of high utilisation across sectors with primary care being 
accessed the most suggesting that supporting GPS to help people manage the condition 
may be worth exploring.   
For those completing the intervention symptom levels for cognition mood 
remained  stable.  Significant improvements were seen in levels of fatigue/energy on 
the SF-36 at follow up.  Greater illness understanding was reported post group that 
which remained at follow up.   Suggesting a period of adjustment is beneficial to allow 
participants to put knowledge into action.  
Although there were no significant differences on healthcare utilisation 
measures, 63% of completers showed improvements in their health states between T1 







ambitious  feasibility project.  Participants welcomed the intervention, feeling it 
exceeded their expectations and resulted in significant improvements in their 
knowledge of their condition.   
Conclusions 
 Results suggest this intervention is a feasible project to introduce further 
exploration of a post diagnosis intervention for those receiving a diagnosis of FND 
within FND Grampian.  Sample sizes were small, as a result the magnitude of the effect 
size in the analyses was unable to be calculated on the current sample.   Overall even 
with a small sample size and reduced power some promising results emerged that 
showed differences in the subscales of health beliefs and quality of life measures for 
attenders and non-attenders as well as completers.  A larger study could explore if these 
subscales hold validity in predicting  who is likely to attend interventions as well as 
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Pearson correlations between duration of symptoms and scores on measures of Cognitive 













Cognitive Function Epitrak Score  .31  .33 -.25 
Mood 
PHQ9 Depression .04  .07 -.03 
GAD7 Anxiety -.29  -.33 -.25 
HRQoL 
EQ-5D VAS -.04  -.19 .38 
SF36 Physical Function -.26  -.37 -.08 
SF36 Physical health 
limitations 
-.16  -.23 .39 
SF36 Emotional health 
limitations 
.27  .35 .13 
SF36 Energy/Fatigue -.07  -.29 .47 
SF36 Emotional Wellbeing .36  .39 .30 
SF36  Social Function .01  .04 -.07 
SF36 Pain -.06  -.24 .19 
SF36 General Health .01  -.20 .40 
Health Beliefs 
IPQ-B Consequences .04  .11 -.16 
IPQ-B Timeline .39
*
  .34 .51 
IPQ-B Personal Control .09  .12 .10 
IPQ-B Treatment Control .15  .31 -.18 
IPQ-B Identity .10  .15 -.07 
IPQ-B Illness Concern .04  -.01 .16 
IPQ-B Coherence .32  .40 .08 
IPQ-B Emotional 
Representation 
-.35  -.35 -.36 
IPQ-B Level of threat  -.16  -.18 -.14 
      








   




Study: A Feasibility Study for a Psychoeducation Group for individuals 
with a  Functional Neurological Disorder 
 
 
Participant ID Number: 
Please initial 
1. I confirm that I have read and understand the information sheet Version No: 2 Date: 
07/01/19 for the above study.  I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
  
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
Data collected up until the point of withdrawal may still be used in analysis. 
 
  
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the sponsor (University of Edinburgh), 
from regulatory authorities if appropriate, or from the NHS Board/Trust, where it is 
relevant to my taking part in this research.  I give permission for these individuals to 
have access to my records. 
 
 
4. I agree to my GP being informed of my participation in the study.  
  
5.  I understand that anonymised quotations from my feedback  may be used for 
presentations and publications. 
 




7. I agree to be contacted by the study team for future studies that they may be 
undertaking. I understand identifiable contact information will be kept after the end of 
this study and this information will be held in accordance with the data protection act.  
 
 













Name of person taking consent Date Signature 
 
Original x 1 to be retained in site file.  Copy x 1 to participant 








This sheet is about a research study that is happening in NHS Grampian. It gives some 
information to help you decide if you want to take part or not. Please read this sheet and 
speak about it with others if you wish. If you have questions, please get in touch with Dr 
Pauline Insch or Dr Fiona Summers on 01224 559352. We are happy to answer any questions 
and would like to thank you for taking time to read this information.  
What is this study about? 
At the moment we do not have any psychological treatments that have been designed  to meet 
the needs of people who have been diagnosed with a Functional Neurological Disorder.    In 
this research we are investigating how useful it is to give patients some additional 
information to help them to explain and manage their symptoms.  This will take the form of a 
small group which will have two sessions, these will be around two weeks apart and each 
session will last for approximately 90 minutes. At present these group sessions are only 
available to participants taking part in the research study.   
Why have I been asked to take part? 
You have been asked as you have been diagnosed with a Functional Neurological Disorder 
by a neurologist in the Department of Neurology, Aberdeen Royal Infirmary.  
Do I have to take part? 
No. It is up to you to make up your mind if you want to take part or not.  If you want to take 
part, please return the study reply sheet and Dr Pauline Insch will contact you.  If you decide 
to take part, and then change your mind you can come out of the study at any time and do not 
have to tell us why. If you decide you do not want to take part, or take part then change your 
mind later, this will not change the care you receive.  
Participant Information Sheet 
Study: A Feasibility Study for a Psychoeducation Group for  
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What will happen to me if I take part?  
The flowchart below shows what taking part in this study would involve. Please see appendix 




Once we receive your reply form Dr Pauline Insch will contact you to arrange an 
appointment that is convenient for you  This appointment will take around 60 minutes, you 
will have the chance to ask any questions you may have and if you are happy to go ahead, 
you will be asked to sign a consent form to give us permission to use your information in the 
research and complete some questionnaires.  Two weeks before the group we will send you 
questionnaires to complete and take with you to the group session. The questionnaires are 
short and take around 20-30 minutes on average in total.  There will be two groups sessions, 
each will last around 90 minutes and be two weeks apart.  At the last session you will be 
asked to complete questionnaires and to give us your feedback on the group you have 
attended.  Three months after the group has ended, we will contact you to arrange a final 
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What will the group be like? 
 
  If you decide to take part you will be asked to attend 2 group sessions spaced a fortnight 
apart which last for approximately 90 minutes.  There will be around 6 people in each group.   
There is no requirement for you to speak about or share your experiences in the group or with 
others attending. The purpose of the group is to provide information that will hopefully allow 
you to understand and manage difficulties associated with your illness.  Information on what 
the group sessions will cover is in the table below 
Session Key Topics 
1 Introduction to FND  What is FND? Making sense of 
symptoms 
 The Brain-Body-Thought Link 
2 Moving Forward with FND  Moving forward: Managing symptoms 
 Obstacles to recovery 
 Signposting to helpful resources 
 
The group aims to help you to: 
 Understand more about what is meant by functional neurological disorder  
 Develop knowledge about how physical and psychological processes interact in the 
body 
 Build knowledge of effective coping strategies and things that may be less helpful. 
 Gain awareness of resources available  
 Have opportunity to meet with others who have been through similar experiences.  
At the end of the second session we will ask you for your feedback about the group this 
feedback will be questionnaire based and anonymous .  
What are the possible disadvantages and risks if I take part? 
It is not likely any harm will come to you if you take part. If however, you feel concerned or 
upset about any issue raised in the questionnaires or in the group content, there will be a 
consultant clinical neuropsychologist present, Dr Fiona Summers, within the group sessions 
to assist you if this is necessary. Information on managing emotions will also form part of the 
group programme.  You can also talk to Dr Pauline Insch or either in the appointment, after 
the group or on 01224 559352. The project team will be happy to discuss any concerns you 
may have.  
 
It may be an inconvenience on your time to complete the questionnaires used in the research 
(see Appendix A at the end of this information sheet, for more information); however, we 
have made every effort to keep these to a minimum and will make every effort to schedule 
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What are the possible benefits if I take part? 
We cannot promise that you will find the group helpful, but we hope having more 
information about your diagnosis and meeting others with Functional Neurological Disorders 
may be beneficial to you and help you manage your symptoms.  Although completing the 
questionnaires outlined in Appendix A may be an additional time commitment for you, we 
hope the information collected from these will help us understand more about some of the 
things patients face when we are developing our treatment options for those that have a 
Functional Neurological Disorder as there is very little information available to clinicians at 
present.  
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential. This information will be coded so no personal details will be available 
from the questionnaires alone,  all personal information is kept separate from study results.  
Procedures for storing data are compliant with the Data Protection Act (2018). The 
identifiable information shall be stored separately from the questionnaires also in a locked 
filing cabinet in NHS Grampian. Electronic data will only be stored on NHS computer server, 
computers are password protected as per local NHS board policy. Only the research team will 
be able to identify participants during the course of the research.  
 
Will my you contact my General Practitioner (GP)? 
We will ask your permission to inform your GP that you are taking part in this feasibility 
study. If you give permission, we will send your GP a copy of this an information sheet 
giving information on this feasibility study and what taking part involves for you. You can 
find out more about how we use your information and our legal basis for doing so in our 
Privacy Notice at: https://www.ed.ac.uk/records-management/privacy-notice-research  
What happens to the results of the research study? 
The results of this study will be submitted as doctoral thesis as part of Dr Pauline Insch’s 
Doctorate in Clinical Psychology training.  In addition, we hope the results will improve the 
service we offer patients within the Neurology Department.  We may also publish the results 
in scientific journals and also present the results at conferences. However, no one will be able 
to recognise you in any report/publication or presentation.  
 
Who is organising and funding the research? 
The project is part of Dr Pauline Insch’s training as part of the Doctorate in Clinical 
Psychology at the University of Edinburgh.  The research has been sponsored by The 
University of Edinburgh and organised by the Department of Clinical Neuropsychology at 
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Who reviewed the study? 
The North East of Scotland Research Ethics Service REC (2), which has responsibility for 
scrutinising NHS research proposals, has reviewed this study and raised no objections from 
the point of view of research ethics.  It is a requirement that all relevant research records are 
made available for scrutiny by monitors from NHS Grampian, whose role is to check that the 
research is properly conducted and the interests of those taking part are protected.  
 
Study Results and Future Research 
We would like to send you information about the results of the study when the research is 
complete.  We would also like your permission to send information about further research 
that may be of interest to you.  These permissions are in the consent form, there is no 
obligation to receive information or hear about potential future research you can still 
participate if you don’t wish to be kept informed or take part in other studies.  
 
Contact for further information 
If you have any questions you can contact Dr Fiona Summers or Dr Pauline Insch on 01224 
559352.   
 
If you would like to speak to someone independent of the study, please contact Dr Jackie 
Hamilton on 01224 559352.   
 
You can also email the study team at nhsg.neuropsych@nhs.net  
 
If you wish to make a complaint about the study you can do this through the usual NHS 
process by contacting the NHS Grampian Feedback service Summerfield House, 2 Eday 
Road, Aberdeen, AB15 6RE, by telephone (0345 337 6338) or by e-mail 
(nhsgrampian.feedback@nhs.net)  
 
If you wish to raise a complaint on how we have handled your personal data, you can contact 
our Data Protection Officer who will investigate the matter. If you are not satisfied with our 
response or believe we are processing your personal data in a way that is not lawful you can 
complain to the Information Commissioner’s Office (ICO) at https://ico.org.uk/.  
Data Protection Officer contact information:  University of Edinburgh, Data Protection 
Officer, Governance and Strategic Planning, University of Edinburgh, Old College, 
Edinburgh, EH8 9YL, by telephone 0131 651 4114 or by email dpo@ed.ac.uk 
Thank you for taking time to read about our project 
 If you want to take part, please complete the accompanying reply form and return 
in the pre-paid envelope provided 
 If you do not wish to participate then please choose the option on the enclosed 
reply form and return in the pre-paid envelope provided. 
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Information sheet Appendix A Study Questionnaires and approximate completion times 
 
 
Baseline Session (One to One) 
 
Questionnaire Description Time to 
complete 
(approximately) 
Informed Consent  A form to get permission from you to take part in the 
research 
5mins or less 
Demographics A form to get background information e.g. your age 
and gender 
5mins or less 
EQ5D A questionnaire about your quality of life related to 
your health 
5mins or less 
Client Services Receipt 
Inventory (CSRI) 
A questionnaire about the Health services you use 
related to your illness 
15 mins or less 
Epi Trak A questionnaire about memory and attention 10 mins or less 
Short Form 36 (SF36) A questionnaire about your quality of life related to 
your health 
10 mins or less 
Brief Illness Perception 
Questionnaire (B-IPQ) 
A questionnaire about what you think about your 
illness 
5mins or less 
Generalised Anxiety 
Disorder 7 (GAD7) 
A questionnaire about Anxiety 5mins or less 
Patient Health 
Questionnaire (PHQ9) 
A questionnaire about Depression 5mins or less 
Approximate time for Baseline Questionnaires  65 mins or less 
 
Pre-Group Session 1 
 
Short Form 36 (SF36) A questionnaire about your quality of life related to 
your health 
10 mins or less 
Brief Illness Perception 
Questionnaire (B-IPQ) 
A questionnaire about what you think about your 
illness 
5mins or less 
Generalised Anxiety 
Disorder 7 (GAD7) 
A questionnaire about Anxiety 5mins or less 
Patient Health 
Questionnaire (PHQ9) 
A questionnaire about Depression 5mins or less 


















Short Form 36 (SF36) A questionnaire about your quality of life related to 
your health 
10 mins or less 
Brief Illness Perception 
Questionnaire (B-IPQ) 
A questionnaire about what you think about your 
illness 
5mins or less 
Generalised Anxiety 
Disorder 7 (GAD7) 
A questionnaire about Anxiety 5mins or less 
Patient Health 
Questionnaire (PHQ9) 
A questionnaire about Depression 5mins or less 
Group Feedback A form asking for your thoughts on the group 
programme 
5mins or less 
Approximate time for Post Group Session 2 Questionnaires 30 mins or less 
 
Follow Up Session 3 months after group (One to One) 
 
EQ5D A questionnaire about your quality of life related to 
your health 
5mins or less 
Client Services Receipt 
Inventory (CSRI) 
A questionnaire about the Health services you use, 
and other costs related to your illness 
15 mins or less 
Epi Trak A questionnaire about memory and attention 10 mins or less 
Short Form 36 (SF36) A questionnaire about your quality of life related to 
your health 
10 mins or less 
Brief Illness Perception 
Questionnaire (B-IPQ) 
A questionnaire about what you think about your 
illness 
5mins or less 
Generalised Anxiety 
Disorder 7 (GAD7) 
A questionnaire about Anxiety 5mins or less 
Patient Health 
Questionnaire (PHQ9) 
A questionnaire about Depression 5mins or less 
Approximate time for follow up session questionnaires  55 mins or less 
Appendix 4: Pre-Post Group Knowledge 



















I know  
a lot  










What FND is.      
How FND is diagnosed      
How Physical and Psychological 
processes interact  
     
What effective coping strategies 
are 
     
What can make symptoms 
worse 
     






Helpful Neutral Unhelpful 
Very 
Unhelpful 
How helpful do you think it 
will be to meet with others 
who have been through 
similar experiences?  
     
 
 
Thank you for your Feedback.  
Department of Clinical Neuropsychology 
Post-Group Evaluation 
 
ID Number:      Workshop Date: 
 









Please mark the box that matches your level of knowledge now you have completed 








Helpful Neutral Unhelpful 
Very 
Unhelpful 
I found meeting others who 
have been through similar 
experiences. 
     
 
 
Thank you for your Feedback.  
 
 
I know  
a lot  










What FND is.      
How FND is diagnosed      
How Physical and Psychological 
processes interact  
     
What effective coping strategies 
are 
     
What can make symptoms worse      
What resources are available       






Group Evaluation Form 
 
Please complete the evaluation form before you leave the final session.  Your views will help us 
review and improve the group for future participants.  Please circle the answer you agree with most, 
there is space for comments if you wish to give more information. 
 
1. The session lasted for 1.5 hours, was this… 
           






2. There were 2 sessions in total, was this… 
           










3. The sessions were spaced a fortnight apart, was this… 
 
Too often A little too often About right 












4. The range of topics covered was 
 








5. The amount of information covered in each session was 
 
Too much A little too much About right 









6. How comfortable was the room and the facilities where the group took place 
 
Very comfortable Quite comfortable Adequate Quite poor Very poor 
 
Comments: 
Please Turn Over 
 
 
7. How approachable were the group facilitators? 
 
Very easy  
to talk to 
Quite easy  
to talk to 
Adequate 
Somewhat difficult 
to talk to 
Very hard  






8. How easy was the information to understand and remember? 
 
Very easy Quite easy  
Neither easy  
or difficult 
















11. Would you recommend this group programme to a friend? 
 
 YES      NO 
 


















Dr Pauline Insch (Chief Investigator) Telephone:  01224 559352 
Department of Clinical Neuropsychology 
Ashgrove House 










Dr Pauline Insch (Chief Investigator) Telephone:  01224 559352 
Department of Clinical Neuropsychology 
Ashgrove House 




Participant ID No______  Date Completed______  Study Stage Baseline 
Demographics  
Study: A Feasibility Study for a Psychoeducation Group for Functional Neurological Disorders 
Meets Inclusion Criteria  (tick to confirm) initials/Date _____/_ _-_ _ - _ _ 
1. D.O.B      / /  
2. Age      ____________________ 
3. Postcode        
4. SIMD        
5. Gender      Male   Female  
6. Date invited     / /  
7. Date Reply Received    / /  
8. Date Contacted    / /  
9. Date of Baseline Appointment  / /  
10. Marital Status  Married/Partner  Single  Widowed  Divorced/Separated 
 
11. Employment Status   F/T Work  P/T Work  Retired      Not Working (Health) 
 Medically Retired   Student 
12. Education 
Years at primary school   Years at secondary school  Age left school  
Number of years in higher or further education  
(Record current year of study if currently undertaking a degree) 
13. Symptom Duration    Years  Months 
14. Age when symptoms began   Years 
Appendix 7: Presenting Symptoms 
 
Primary Presenting Symptom Categories  
 
Sensory  
Numbness, tingling in the face, body or limbs.  
Pain in the face, body or limbs 
Functional visual symptoms  







Functional limb weakness/paralysis 
Functional movement disorders; including tremor, spasms (dystonia), jerky movements (myoclonus) 
and problems walking (gait disorder) 
Functional speech symptoms; including whispering speech (dysphonia), slurred or stuttering speech 
 
Altered Awareness 





Physical and psychological symptoms experienced by patients with FND  
Fatigue 
Sleep problems 
Bowel and bladder problems  










Pre-Group Expectations Post-Group Expectations 
PT02 To help educate professionals about FND so 
that future FND patients know more about 
their disorder and not [feel] confused or feel 
fobbed off 
 
Yes they were 
PT03 To be very honest I have no expectations other 
than it will increase my awareness and 
perhaps help the FND cause in Grampian 
NHS 
Yes. I found the group session to be very 
informative and reassuring. Well done for 




PT08 Meet others and share experiences to do with 
FND. Get a better understanding on what 
FND actually is and possibly how to manage 
symptoms 
 
I found the group really helpful for more of an 
understanding of FND 
PT12 meet others like self and see how to cope on 
day and daily basis and see if anything can 
help 
Yes - nice to see others with similar 
symptoms, gave understanding of why body is 
doing what [it is] doing and being given info' 
in finding others/body 
 
 
PT13 To meet other people with the problems with 
FND 
Yes.  The group was very helpful, I realised 
I'm not alone 
PT16 finding out what FND is and what is available 
to those who suffer from it. Maybe find link 
between FND and PTSD. What treatments (if 
any) are available 
To be honest I did not have any expectations 
preferring to keep an open mind as I had went 
through similar groups relating to PTSD and 
was disappointed. I did however find this 
group very helpful, especially meeting others 
who suffer from FND  
 
PT17 To understand more about my condition, learn 
how to manage my symptoms, learn what can 
make symptoms worse, find out what 
resources there are available, learn what 
lifestyle choices I can make 
Yes it was great to be part of the study.  The 
group sessions gave me peace of mind.  I 
really appreciated running through coping 
strategies and the bit about what can make 
symptoms worse.  
 
 
PT19 increase awareness to what it actually is. 
Listen to other people's understanding 
They certainly were. I wasn't initially sure of 
what to expect but as it was a small group we 







PT24 Mutual support and a sense of understanding. 
Opportunity to build in shared experiences to 
improve experiences for others coming to a 
diagnosis 
 
Yes - made useful by good balance of info and 
experiences of others 
PT25 I would like to find out more about how I feel 
and if there are others in the same position 
My expectations of group are more than met - 
fantastic discussions about feelings and FND 
 
 
PT26 How to move forward with FND, meeting 
peer group, shaping support for those with 
FND diagnosis in the future 
Yes and more!  The new FND leaflet is 
inspired.  
PT28 Finding out more about FND. Meeting new 
people with the same diagnosis as yourself, 
meeting new people and making new 
friendships 
 
I learned a lot about FND and what to do now 
I know it's not my fault and I'm not alone 
 
 
PT23 How to better manage day to day life and have 
a better understanding of anatomy processes if 
available 
Yes - well presented, good balance of info and 
personal discussion. Info presented to best of 
their knowledge. I understand its limited due 
to research 
 











4 A little short Feel as quite few slides maybe a Q+A at the end 
6 A little short Felt it couldn't lasted 2 hours maybe 
7 A little short 
Time was good in terms of illness, but felt there 
could be a lot more discussion about each other’s 
experiences 
8 A little short 
Extend to two full ours with a 15 min break in 
between 
 
Q2 There were 2 sessions in total was this… 
1 Not quite enough 
Group discussions were great, I would have liked 
more time to get to know them a little better. 
4 Not quite enough 
Think a third meeting would be good, of feel 
enough points to consider. 
6 Not quite enough 
I would prefer more, just as it was great for info. 
And others with similar. 
8 About right 
Alternatively have the two sessions in one day 
due to participants' long travel 
 
Q3 The sessions were spaced a fortnight apart, was this… 
2 Not quite often enough Weekly sessions 
4 Not quite often enough 
Felt if it was weekly I would take it in better as 
my memory is bad.  
11 Not quite often enough A week apart 
Q4 The range of topics covered was... 
4 About right Topics good, more time on each 
Q5 The amount covered in each session was.. 
2 About right 
I would have preferred weekly sessions over 4-6 
weeks to give a bit more time to take in and 
think about the discussions and recap and talk 








2 Very Comfortable Nice and warm friendly atmosphere 
4 Very Comfortable Room was fine 
 
Q7 How approachable were the group facilitators.. 
2 Very easy to talk to 
The information videos were very helpful and 
explained by the tutors present 
4 Very easy to talk to Very approachable 
6 Very easy to talk to 
Was very relaxed atmosphere and very helpful in 
discussions 
7 Very easy to talk to Very approachable facilitators 
Q8 How easy was the information to understand and remember? 
 
2 Quite easy Tutors gave clear answers to questions 
4 Very easy Understand ok, remembering difficult. 
6 Very easy Very easy but my fault for not remembering  
9 
Neither easy nor 
difficult 
Mainly because my memory isn’t that great at 
the moment. 
Q9 Was there anything about the group you particularly liked? 
1 The friendliness, meeting the others and the professionals 
2 The friendliness between the tutors and patients 
3 The information and banter 
4 The camaraderie and easily approachable psychologists 
5 Everything 
6 More people in the same boat as me and the helpful staff 
7 Semi-structured and allowed for discussion 
8 
How informal and friendly it was.  The facilitators would listen to your 
experiences 
9 I like how at ease and interesting it was 
10 
Friendly open conversations.  It was good to hear how others deal with 
FND. 
11 
I liked how FND was normalised and acknowledged that many GP’s do not 
know about it  
 
 
Q10 Was there anything about the sessions you would change? 
1 
A little more discussion amongst the group would be helpful but possibly 
not for everyone. 
2 Spread over longer period maybe 4-6 weeks 
3 No  
4 No thought they were fine 
5 No 
6 Just more time for discussions really as can get in-depth 
7 Add discussion times between participants whether in pairs or groups 
8 No 
9 
Perhaps some more time for people to ask questions or tell experiences.  
Our group was quite small so might be harder in a larger group.  
10 No 
11 
The videos were good but there was a lot of information to digest and 
interact with very quickly.   
Q11 Would you recommend this group to a friend 
100% of participants said yes 
Q12 Further comments 
1 Great progress for patients and families dealing with FND 
2 
Felt very much at ease with tutors could ask them anything you were 
unsure of and had a lot of laughs with them.  They were patient and 
friendly and answered everything that was asked of them.  I found the 
sessions very helpful in many ways especially knowing I was not alone 
with my problems and I could do a lot to help myself and now I know 
how to deal with them. 
 
3 
Overall pleased with the programme, it gave good insight into FND and 
gave further resources for once the programme completed.  
4 Very interesting meeting people with the same diagnosis as yourself 
5 
It was great to have the chance of being part of such a complex study.  It 
also helped me understand more about FND and the minefield that it 
comes with 
9 I would definitely recommend to any others with FND or family etc 
10 
This was a well thought out group meeting where we learned a lot about 
FND that had not been explained to us when we were all diagnosed.  I 
am really glad I had the opportunity to attend. 
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Dr Pauline Insch 
NHS Grampian 
Trainee Clinical Psychologist  
Dept of Neuropsychology 
Aberdeen Royal Infirmary 
Aberdeen 
AB25 2ZN 
     
 
Date  18/01/2019 
Project No 2018PC011 
 
Enquiries to Lynn / Louise  
Extension 53846 






Dear Dr Insch 
 
Management Permission for Non-Commercial Research 
 
 
STUDY TITLE: A feasibility study for a psychoeducation group intervention for people with 
Functional Neurological Disorder (FND)   
PROTOCOL NO: V1; 13.9.18 
REC REF: 18/NS/0137  




Thank you very much for sending all relevant documentation.  I am pleased to confirm that the 
project is now registered with the NHS Grampian Research & Development Office.  The project 
now has R & D Management Permission to proceed locally.  This is based on the documents 
received from yourself and the relevant Approvals being in place. 
 
All research with an NHS element is subject to the UK Policy Framework for Health and Social 
Care Research (2017 v3), and as Chief or Principal Investigator you should be fully committed to 
your responsibilities associated with this. 
 
 
R&D Permission is granted on condition that: 
 
1) The R&D Office will be notified and any relevant documents forwarded to us if any of the 
following occur: 
 Any Serious Breaches in Grampian (Please forward to pharmaco@abdn.ac.uk).  
 A change of Principal Investigator in Grampian or Chief Investigator.  
 Any change to funding or any additional funding  
 
 
2) When the study ends, the R&D Office will be notified of the study end-date.  
 
3) The Sponsor will notify all amendments to the relevant National Co-ordinating centre. 






We hope the project goes well, and if you need any help or advice relating to your R&D 









cc:  Sponsor – Charlotte Smith, Edinburgh 




Sponsor: University of Edinburgh  
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